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ABSTRACT 
 
The potassium-chloride cotransporter KCC2 is a key regulator of chloride homeostasis in 
neurons of the central nervous system (CNS) and it is critical for the development of fast 
hyperpolarizing synaptic inhibition. Two full-length isoforms of KCC2, KCC2a and KCC2b, 
differing by their amino termini have been described. Both isoforms have similar expression 
levels in neonatal mice, but KCC2b is strongly upregulated in cortical areas during postnatal 
development, resulting in a developmental shift of GABAergic responses. In contrast to the 
well-studied KCC2b isoform, the importance of the KCC2a isoform has not yet been 
demonstrated. My thesis work focuses on characterizing the transcriptional regulation, 
expression and function of the KCC2 isoforms and a central aim is to elucidate the isoform-
specific differences. 
 
The molecular mechanisms underlying the regulation of KCC2 gene expression are not yet 
well understood. Both isoforms show a largely neuron-specific expression pattern and their 
expression is tightly regulated in development. The KCC2b isoform is also known to be 
regulated by both normal and pathological neuronal activity. One aim of the present thesis 
work was to explore the functionality of a conserved E-box site in the KCC2b promoter. 
Results suggest that the E-box site functions as a binding site for the upstream stimulating 
factors 1 and 2 (USF1, USF2), two basic helix-loop-helix transcription factors with potentially 
important roles in brain. Binding of USF proteins to the E-box motif contributes to the 
upregulation of KCC2b gene expression in immature cortical neurons. 
 
Another aim of this study was to compare the postnatal expression patterns of KCC2a and 
KCC2b proteins in various regions of mouse CNS using immunohistochemistry and 
isoform-specific antibodies. The cellular expression patterns of KCC2a and KCC2b were 
largely similar in developing and neonatal mouse. In mature brain, KCC2a is detected in the 
basal forebrain, hypothalamus, and many areas of the brainstem and spinal cord, but its 
expression is very low in cortical regions. At the subcellular level, immunoreactivities of the 
isoforms are only partially colocalized, and KCC2a immunoreactivity, in contrast to KCC2b, 
is not clearly detected at the neuronal soma surface in most brain areas. Biotinylation 
experiments suggest that the N-terminal KCC2a epitope might be masked.  
 
Results of this thesis work also indicate that the KCC2a isoform, similar to KCC2b, can 
function as a chloride transporter and decrease the intracellular chloride concentration in 
cultured neurons. The unique N-terminus of KCC2a includes a SPAK kinase binding site, 
and the importance of this site and the WNK-SPAK signaling pathway is also explored. Our 
results indicate that the SPAK kinase is able to bind the KCC2a isoform and to regulate the 
transport activity of KCC2a more than that of KCC2b. 
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1. REVIEW OF THE LITERATURE 
 
1.1 THE CCC FAMILY AND KCC2 
 
The electroneutral cation-chloride cotransporters (CCCs) are integral plasma membrane 
proteins that belong to the solute carrier 12 (SLC12) gene family. CCCs mediate the coupled 
transport of Cl- and cations (K+ and/or Na+) across the plasma membrane. The gradients of 
Na+ and K+ are established by the Na+-K+-ATPase and provide the energy for the transport 
of Cl-. Under normal physiological conditions the Na+ driven cotransporters transport 
chloride into the cell, while chloride efflux is powered by the K+ driven cotransporters. 
However, CCCs are bidirectional and can mediate a net efflux or influx, depending on 
existing ionic gradients (Gamba, 2005, Kaila et al, 2014). 
 
In mammals the CCC family has nine members: Na+ driven CCC members include two Na+ 
-K+ -2 Cl− cotransporters (NKCC1-2), and one Na+ - Cl− cotransporter (NCC), while K+ 
driven CCCs include four K+- Cl− cotransporters (KCC1-4).  CCC9 and the CCC interacting 
protein 1(CIP1) are also members of the CCC family but their physiological role is not known 
(Gagnon and Delpire, 2013).  
 
Significant isoform diversity within the CCC family is generated by alternative splicing events, 
and the isoforms often demonstrate differences in tissue distribution or functional 
characteristics (Gamba, 2005). Expression and function of CCCs is regulated at the 
transcriptional and post-translational levels. Phosphorylation-dephosphorylation, in 
particular, is a key mechanism of regulation of CCCs at the protein level (Medina et al, 2014). 
 
Important functional roles of CCCs include intracellular Cl- homeostasis and cell volume 
regulation, as the transported ions are also accompanied by water (Kahle et al, 2015). Some 
members also have specific roles in epithelia and neurons. Of the N+ driven cotransporters, 
NKCC1 is widely expressed and has various functions in Cl- homeostasis, cell volume 
regulation and epithelial transport. NKCC2 and NCC are involved in renal salt reabsorption 
in the kidney, but expression NKCC2 has also been observed in the hypothalamo-
neurohypophyseal system in rat brain (Konopacka et al, 2015). Of the K+ driven 
cotransporters, KCC1 is ubiquitously expressed while KCC3 and KCC4 have a somewhat 
more restricted expression (Gillen et al, 1996, Mount et al, 1999). KCC3 is expressed in various 
tissues, including brain, and it is particularly important for cell volume regulation following 
hyposmotic swelling (Rust et al, 2006, Boettger et al, 2003, Byun and Delpire, 2007). KCC4 is 
known to function in transepithelial transport in the inner ear and kidney (Boettger et al, 
2002). 
 
Among the KCCs, KCC2 is unique as it is central nervous system (CNS) neuron specific and 
has important functions in neurons, especially as it mediates an efficient Cl- extrusion in 
mature neurons (Payne et al, 1996, Rivera et al, 1999, Hubner et al, 2001). The intracellular Cl- 
concentration of neurons determines the strength and polarity of transmission via type A γ-
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aminobutyric acid (GABA) receptors and glycine receptors, which are both Cl−-permeable 
ion channels. KCC2 also appears to interact with components of the cytoskeleton in neurons, 
and to play an important morphogenic role in dendritic spine formation and function of 
excitatory synapses in the CNS (Li et al, 2007, Fiumelli et al, 2013, Horn et al, 2010, Llano et 
al, 2015, Gauvain et al, 2011). 
 
The KCC2 gene generates two splice variants, KCC2a and KCC2b, by two alternate first 
exons under control of separate promoters (Uvarov et al, 2007). KCC2a and KCC2b isoforms 
differ only in the amino (N)-terminus encoded by these two alternate first exons. In the 
neonatal mouse brain, the two KCC2 isoforms have similar protein levels and distribution, 
are co-expressed in many neurons (Uvarov et al, 2009). The KCC2a protein shows only 
moderate increase during postnatal development whereas KCC2b is strongly upregulated in 
development. In adult mouse brain, KCC2b is the predominant isoform and KCC2a makes 
up less than 10% of the total KCC2 (Uvarov et al, 2007, Uvarov et al, 2009).  
 
Members of the CCC family are associated with various diseases, and KCC2 in particular has 
been associated with neurological or neuropsychiatric diseases. Downregulation of KCC2 
expression or activity is associated with elevated levels of intracellular chloride, resulting in 
enhanced neuronal activity, hyperexcitability and seizures. Epileptiform activity has been 
observed in studies in animal models (Rivera et al, 2002, Rivera et al, 2004) and humans 
(Huberfeld et al, 2007). Mutations in KCC2 have also been shown to be associated with 
epilepsy in humans (Kahle et al, 2014, Puskarjov et al, 2014, Stodberg et al, 2015, Saitsu et al, 
2016). Downregulation of KCC2 is also observed for example in neuropathic pain (Coull et 
al, 2003), brain trauma (Shulga et al, 2008) and spasticity after spinal cord injury (Boulenguez 
et al, 2010). 
 
Moreover, changes in KCC2 gene transcription from early stages may contribute to the 
genetic risk of neurodevelopmental disorders in humans. Dysregulation of Cl− homeostasis 
and abnormalities in GABA signaling during development may disrupt the trophic effects of 
GABA and affect a variety of developmental processes such as migration, differentiation, 
synapse maturation, and neuronal wiring (Cellot and Cherubini, 2014). Changed expression 
of chloride cotransporters has been implicated in autism spectrum disorders such as Rett 
syndrome (Tang et al, 2016) and Fragile X syndrome (He et al, 2014, Tyzio et al, 2014) and 
schizophrenia (Hyde et al, 2011, Tao et al, 2012) .   
 
 
1.2 THE KCC2 GENE 
  
1.2.1 Gene structure 
 
The CCC family is highly conserved in evolution, and homologs of CCCs are present in 
various eukaryotes (Gagnon and Delpire, 2013). Prokaryotic homologs of the CCC family 
have also been identified. Many species of vertebrates have four genes encoding K+-driven 
transporters (KCC1-4; genes Slc12a4-7) as well as three Na+ -driven transporters (NKCC1 
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and 2 and NCC; genes Slc12a1-3). During vertebrate evolution, the ancestral KCC coding 
gene probably gave rise to KCC1 and KCC3 in one duplication and KCC2 and KCC4 in 
another duplication, resulting in the four KCCs (Gagnon and Delpire, 2013, Hartmann et al, 
2014). 
 
In Drosophila melanogaster there are five CCC genes including one kcc-like gene (kazachoc) 
(Rusan et al, 2014). The kcc gene of drosophila is important for inhibitory neurotransmission 
(Hekmat-Scafe et al, 2006), suggesting that the K+ -driven transporters initially evolved to 
serve this particular function in the nervous system. The Caenorhabditis elegans genome 
contains seven CCC isoforms including three KCC genes, and the function of one (ce-KCC2) 
is important for inhibitory neurotransmission and synapse maturation (Tanis et al, 2009).  
 
The mammalian KCC2 gene (Slc12a5) consists of 27 exons and is located on chromosome 2 
in mouse (Fig. 1A,B). The gene has two alternative first exons (1a and 1b) and two  transcripts 
with 26 exons are generated, each encoding a full-length protein isoform with a predicted 
topology of twelve transmembrane spanning segments and intracellular N- and C –termini 
(Uvarov et al, 2007, Payne et al, 1996) (Fig. 1C). KCC2a transcripts lacking exon 24 are 
expressed in pancreatic β-cells and in adrenal medullary cells (Kursan et al, 2017) (Fig. 1C).  
 
The coding part of the first exon of KCC2a in mouse contains 121 base pairs (bp) (encodes 
40 amino acids), while the coding part of the first exon of KCC2b contains 52 bp (encodes 
17 amino acids) (Fig. 2).  
 
The exon structure of the KCC genes is quite similar in mammals, but exons 22 and 24 of 
KCC2 (encoding portions of the C-terminal domain), are absent from KCC genes in most 
mammals (Payne et al, 1996). Exon 22 of KCC2 (encodes 41 amino acids), is absent from 
KCC1 and KCC3 genes of vertebrates, but it is present in KCC4 of lower vertebrates, 
including fish, birds, and a prototherian mammal (platypus). Exon 24 of KCC2 (encodes 5 
amino acids) is also missing in most KCCs, but it has been identified in some alternatively 
spliced variants of the KCC4 gene (Slc12a7) in mammals (Antrobus et al, 2012).  
 
Several truncated transcripts have been described for KCC2b in patients with schizophrenia 
(Tao et al, 2012), but the significance of these transcripts is not known, as the encoded 
proteins would most likely be non-functional in ion transport.  
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Fig.1 Chromosome location, gene structure and full-length transcripts of Slc12a5 
A) The Slc12a5 gene is located on chromosome 2 in mouse. The nucleotide base pairs 
indicate the start and stop of the gene according to the assembly GRCm38 for mouse.  
B) Exon organization of the Slc12a5 gene: exons are illustrated as boxes, introns as lines 
(the latter are not drawn to scale). The full-length protein isoforms have a predicted 
topology of twelve transmembrane spanning segments and intracellular N- and C –termini 
and these different domains are depicted here as colored regions of the coding exons: 
transmembrane domains (pink), intracellular parts (blue), extracellular parts (yellow). 
Main transcription start sites are shown by black arrows, and a minor transcription start 
site is represented by a gray arrow (Payne et al, 1996, Uvarov et al, 2005). 
C) Full-length KCC2a and KCC2b mRNA transcripts, consisting of 26 exons each, with 
alternatively spliced first exons are generated. Untranslated regions (UTRs) of transcripts 
are represented by white boxes. Alternative splicing of exon24 (marked by an asterisks) 
generates a KCC2a variant identified in pancreas.  
 
 
 
Fig. 2 Coding parts of exon 1a and exon 1b 
Sequences of the coding parts of exon 1a (121 bp) and exon 1b (52 bp), as well as 
encoded amino acids, are shown. 
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1.2.2 mRNA expression pattern  
 
In situ hybridization using probes detecting both KCC2 isoforms show that KCC2 mRNA 
expression is strongly upregulated during development and the upregulation is correlated 
with the maturation of neurons in rodents (Li et al, 2002, Wang et al, 2002, Stein et al, 2004). 
KCC2 mRNA is observed in differentiated neurons but not in neuronal precursors or in 
migrating cells (Li et al, 2002, Wang et al, 2002, Stein et al, 2004). The first KCC2 transcripts 
are detected in mice in the ventral horn of the spinal cord and in the immature brainstem by 
embryonic day 10.5 (E10.5) (Stein et al, 2004). Gradually the expression spreads in a caudal-
rostral fashion: At E14.5, expression is found in the diencephalon, in hypothalamus, ventral 
thalamus and ventral lateral geniculate nucleus and moderate levels are observed in the dorsal 
parts of thalamus. In telencephalon, expression can be seen in the olfactory bulb at this time-
point (Li et al, 2002, Wang et al, 2002, Stein et al, 2004).  
 
At postnatal day 0 (P0), KCC2 mRNA expression has spread throughout diencephalon, and 
a few regions of telencephalon show expression: namely basal ganglia, piriform cortex, 
amygdala and olfactory bulb (Li et al, 2002, Wang et al, 2002, Ikeda et al, 2003). During further 
postnatal development, expression gradually spreads into higher brain structures such as 
neocortex, hippocampus and cerebellum. The adult level and pattern of KCC2 mRNA 
expression, including strong expression in neocortex and hippocampus, is reached at P15 in 
mice (Stein et al, 2004, Wang et al, 2002, Rivera et al, 1999). The KCC2 mRNA expression 
follows a similar pattern in mouse and rat, but in rat expression is delayed by approximately 
two days (Li et al, 2002).  
 
KCC2 transcripts are expressed in mature neurons throughout the CNS but not in PNS 
(except for some regions, see below). Some CNS areas where KCC2 mRNA has not been 
detected are the mesencephalic trigeminal nucleus (Kanaka et al, 2001, Toyoda et al, 2005), 
vasopressin-positive neurons in the thalamus (Bartho et al, 2004, Kanaka et al, 2001), 
dopaminergic neurons in substantia nigra pars compacta (Gulacsi et al, 2003), dorsolateral 
part of the paraventricular nucleus (Kanaka et al, 2001), dorsomedial part of the 
suprachiasmatic nucleus (Kanaka et al, 2001), ventromedial part of the supraoptic nucleus 
(Kanaka et al, 2001, Leupen et al, 2003), reticular thalamic nucleus (Kanaka et al, 2001, Bartho 
et al, 2004) and medial habenular nucleus (Kanaka et al, 2001).  
 
Only the KCC2b isoform undergoes strong up-regulation during postnatal development, 
whereas KCC2a mRNA expression remains relatively constant (Uvarov et al, 2007). In 
quantitative real-time PCR, the KCC2a and KCC2b mRNA expression was detected in the 
brainstem, spinal cord, and olfactory bulb at E17, and the relative expression of the isoforms 
was similar in these brain regions. KCC2a and KCC2b mRNA signals were very low in cortex 
and hippocampus at E17. Between E17 and P14, relative KCC2b mRNA levels increased 
strongly in the neocortex (by 35-fold) and hippocampus (by 10-fold), while relative KCC2a 
mRNA levels did not change significantly (increased only ~2-fold in cortex, and decreased 
slightly in hippocampus, spinal cord and brain stem). In adult mouse brain the level of KCC2a 
mRNA consisted of only 4–8% of total KCC2 mRNA, as measured by RNA protection assay 
(Uvarov et al, 2007).  
6 
 
 
The expression pattern of KCC2 isoforms is largely CNS neuron specific (Payne et al, 1996, 
Uvarov et al, 2007). However, KCC2 transcripts have been detected in cultured rat vascular 
smooth muscle cells (Di Fulvio et al, 2001) and several human cancer cell lines (Wei et al, 
2011). KCC2a transcripts have also been detected in human lens epithelial cells (Lauf et al, 
2012), in chicken cardiomyocytes (Antrobus et al, 2012) and in pancreatic beta cells (Kursan 
et al, 2017). 
 
 
 
1.2.3 Regulation of gene expression 
 
1.2.3.1 KCC2 promoter regions 
 
The main transcription start sites and the core promoter region of KCC2b gene have been 
identified (Payne et al, 1996, Uvarov et al, 2005) (Fig 3). No typical TATA or CAAT boxes 
are present in the KCC2 promoter region. In transiently transfected mouse neuroblastoma 
N2a cells, an approximately 300bp sequence region upstream of the main TSS was sufficient 
to provide a basal level of KCC2 promoter activity, and most of the basal activity was defined 
by the sequence −180 to +42 around the TSS region (Uvarov et al, 2005, Uvarov et al, 2006, 
Uvarov et al, 2007). The activity of a KCC2 promoter construct containing intron 1b 
sequence was inhibited in N2a cells, and thus a downstream response element within the 
intron 1b region presumably functions as a transcriptional silencer (Uvarov et al, 2005). The 
KCC2a promoter region (approximately 1 kb of mouse genomic sequence upstream of the 
KCC2a TSS) also possesses transcription activity in cultured neurons (Uvarov et al, 2007).  
 
Several consensus sequences of transcription factor binding sites conserved in mammals have 
been identified in the KCC2b promoter and proximal intron-1 regions (Uvarov et al, 2006) 
(Fig 3). The -180/+42 region contains only the TSS and Sp1 and AP2 consensus sequences. 
Early growth response 4 (Egr4) binds to an Egr-responsive element in the KCC2b promoter 
(Uvarov et al, 2006). Two conserved neuron-restrictive silencing elements (NRSEs) (also 
called RE1 motif) associated with the KCC2 gene have been shown to bind neuron-restrictive 
silencer factor NRSF (also called repressor element-1 silencing transcription factor, REST) 
(Karadsheh and Delpire, 2001, Uvarov et al, 2005, Yeo et al, 2009). The predicted proximal 
KCC2a promoter contains a putative TATA box and conserved binding sites for ubiquitous 
transcription factors such as E2F and HNF4 but no obvious conserved sites for neuron-
enriched transcription factors (Uvarov et al, 2007). 
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Fig. 3. KCC2b promoter region  
Schematic representation of the KCC2 genomic region with isoform specific promoters 
indicated. Five putative CpG islands (shown in green) are predicted within the KCC2 
genomic region: one in the promoter/5′-UTR region of exon1a, three in the KCC2b 
promoter/5′-UTR region, and one in the 3′-UTR region of the KCC2 gene (Uvarov et al, 
2005, Uvarov et al, 2007). The upstream promoter region of exon 1b and part of intron 1b 
are shown in detail. Positions of TSSs are indicated by curved arrows: The main TSS, 
where 90-95% of transcripts are started, is designated by +1 (black curved arrow). Several 
minor transcription initiation sites are present further upstream, the most upstream is 
indicated (gray curved arrow). The translation initiation codon (ATG) is indicated. The 
region showed in blue, located −435 to +9 around the TSS, is predicted to be the core 
promoter of the KCC2 gene and has a GC content above 70%. Potential binding sites for 
transcription factors are shown: neuron-restrictive silencer element (NRSE), activating 
enhancer-binding protein 1 (AP1) and 2 (AP2), myocyte-enhancing factor 2 (Mef2), E-
box, specificity protein 1 (Sp1), early growth response 4 (Egr4), block1. Binding of 
transcription factors Egr4 and neuron-restrictive silencer factor (NRSF), which are both 
implicated in KCC2b gene regulation, are shown.  
 
 
 
1.2.3.2 Mechanisms of KCC2 gene regulation 
 
KCC2 mRNA expression follows neuronal maturation and synaptogenesis (Li et al, 2002, 
Gulyas et al, 2001, Rivera et al, 2005). Suggested mechanisms underlying the KCC2 
upregulation in development include depolarizing responses to GABA in immature neurons 
and the resulting influx of Ca2+ via voltage-gated calcium channels (Ganguly et al, 2001). 
However, it has been shown that neither GABA type A receptor activation, extrasynaptically 
released GABA, synaptic transmission or action potentials were necessary for the expression 
of KCC2 in development (Ludwig et al, 2003, Titz et al, 2003, Wojcik et al, 2006). Therefore, 
other factors related to the maturation and synapse-formation might be important, such as 
cell to cell interactions and the release of growth factors (Ludwig et al, 2003, Kelsch et al, 
2001, Aguado et al, 2003). 
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Brain derived neurotrophic factor (BDNF) favors KCC2 mRNA expression in immature 
hippocampal neurons (Ludwig, Uvarov, Soni et al, 2011). BDNF binds to the tropomyosin 
receptor kinase B (TrkB) receptor and activates intracellular cascades that results in the 
activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway and the 
mitogen-activated protein kinase (MAPK) pathway. Activation of ERK1/2 induces 
enhanced Egr4 expression and Egr4-dependent increase of KCC2 (Ludwig et al, 2011). The 
trophic factor neurturin also increases KCC2 expression in developing neurons via the 
ERK1/2 pathway, triggering Egr4 mRNA expression and upregulates the KCC2 protein 
(Ludwig, Uvarov, Pellegrino et al, 2011).  
 
A decrease in KCC2 mRNA has been observed in several pathological conditions for 
example  in epilepsy (Palma et al, 2006, Huberfeld et al, 2007), chronic pain (Coull et al, 2003), 
spasticity after spinal cord injury (Boulenguez et al, 2010), motor neurons after axonal injury 
(Nabekura et al, 2002, Toyoda et al, 2003, Shulga et al, 2008, Shulga et al, 2009), and in spinal 
cord neurons after sciatic nerve lesion (Coull et al, 2003). Activity-dependent regulation of 
KCC2 mRNA has been observed in hippocampal neurons after kindling-induced seizures 
and exogenous BDNF application (Rivera et al, 2002). In mature hippocampal neurons, 
sustained interictal-like activity induced BDNF release and the BDNF-TrkB signaling 
resulted in a down regulation of KCC2 gene expression via the transcription factor cAMP 
response element-binding protein (CREB) (Rivera et al, 2004).  
 
KCC2b mRNA is specifically expressed in neurons of the CNS, and one mechanism that 
may contribute to the neuron-specific expression of KCC2b is the NRSF binding to NRSE 
sites in the KCC2 gene. The NRSF functions to suppress transcription of NRSE containing 
genes in non-neuronal tissues by assembling a multiprotein complex to modify covalent 
modification of chromatin (Schoenherr and Anderson, 1995, Naruse et al, 1999, Roopra et al, 
2000). The NRSE in the KCC2 intron-1b has been demonstrated to interact with the NRSF 
and suppress the transcriptional activity of the KCC2 1b promoter in vitro (Karadsheh and 
Delpire, 2001). Another NRSE in KCC2 intron 1a (1.8 kb upstream of the KCC2b TSS) also 
mediated transcriptional inhibition of the KCC2b in vitro ((Karadsheh and Delpire, 2001, 
Uvarov et al, 2005, Yeo et al, 2009). However, NRSF binding seems not to be essential for 
the neuron-specific expression pattern of KCC2 since a KCC2 transgene containing a 1.4kb 
genomic fragment containing neither of the two NRSE sites was still expressed 
predominantly in CNS neurons in transgenic mice (Uvarov et al, 2005). 
 
Epigenetic factors including DNA methylation and proteins binding methylated DNA might 
be important in controlling the expression of the KCC2 gene. The methyl-CpG binding 
protein 2 (MeCP2) has been implicated in KCC2 gene regulation via inhibiting NRSF binding 
to the NRSE sites and thus preventing NRSF mediated  inhibition of KCC2 expression (Tang 
et al, 2016). In Rett neurons, where MeCP2 is deficient, NRSF can bind to the NRSE sites 
and suppress KCC2 expression (Yeo et al, 2009). DNA methylation and MeCP2 binding was 
observed to exert a repressive effect on 2.5 kb of the KCC2 promoter surrounding the TSS 
(Yeo et al, 2013). Several CG dinucleotides that are methylated in non-neural tissues but 
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unmethylated in neurons were identified in the KCC2b promoter and methylation might be 
important in the neuron-specific expression of KCC2. 
 
The 3′-UTR region of the KCC2 gene is long and contains a CpG island (Uvarov et al, 2007). 
A putative promoter situated in the 3′-UTR region was suggested to drive an antisense RNA 
that can inactivate the KCC2 gene (Akan et al, 2009). The KCC2 3’-UTR region also contains 
several conserved target sites for microRNA-92 which was found to interact with KCC2 
mRNA and reduce its translation (Barbato et al, 2010). Training mice in contextual fear 
conditioning produced a transient increase in microRNA-92 levels in the hippocampus that 
lead to the downregulation of KCC2 protein (Vetere et al, 2014).  
 
 
 
1.3 KCC2 PROTEIN ISOFORMS 
 
1.3.1 Structure and interactions 
 
The full-length KCC2 transcripts in mouse encode proteins with 1138 (KCC2a) and 1115 
(KCC2b) amino acids, and predicted molecular mass of ~125 kDa (Uvarov et al, 2007). The 
predicted topology of the full-length plasmalemmal CCC family members consists of 12 
alpha-helical transmembrane segments flanked by intracellular amino (N) and carboxy (C) 
terminals (Payne et al, 1996) (Fig. 4). A large glycosylated extracellular loop is present between 
transmembrane domains 5 and 6 in KCCs, and the glycosylated molecular mass of KCC2 is 
~140 kDa (Payne et al, 1996). Six glycosylation sites have been identified by mass 
spectrometry (Agez et al, 2017) (Fig. 4). 
 
The long intracellular C-terminal domain is highly conserved among CCCs. The C-terminal 
domain of KCC2 seems to be important for surface stabilization, as truncation of the C-
terminus resulted in rapid internalization (Friedel et al, 2017).The C-terminal domain also 
influences the cotransport function of KCC2 (Casula et al, 2001, Shen et al, 2003, Li et al, 
2007, Horn et al, 2010, Fiumelli et al, 2013, Strange et al, 2000). KCC2 is the only KCC that 
exhibits activity under isotonic conditions while the three other KCCs need to be activated 
by hypotonic conditions. The isotonic activity of KCC2 is provided by a unique ISO-domain 
in the C-terminal part of the transporter, encoded by residues in exon 23 (Mercado et al, 2006, 
Acton et al, 2012).  
 
The KCC2 protein contains several sites important for functional regulation and protein-
protein interactions (Fig. 4). Cysteine residues in the large extracellular loop of KCC2 (C287, 
C302, C322, C331) (Hartmann et al, 2010), as well as a cysteine residue C568 in the 10th 
putative transmembrane domain (Reynolds et al, 2008) are important for the ion transport 
activity of KCC2. C568 is possibly also important for structural interactions of KCC2 with 
the cytoskeleton (Horn et al, 2010). Leucine 675 (L675) is also involved in KCC2 ion-
transport activity (Doding et al, 2012).  Several missense mutations in KCC2 in humans have 
been associated with epilepsy: R952H and R1049C (Kahle et al, 2014, Puskarjov et al, 2014), 
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L426P, G551D and L311H (L403P, G528D, and L288H in KCC2b) (Stodberg et al, 2015), 
M415V A191V S323P, as well as a deletion in the N-terminus (E50-Q93) by skipping of exon 
3 (Saitsu et al, 2016). The mutation W318S and a deletion of S748 in the C terminus were also 
identified, but the impact of these mutations on KCC2 was not examined. Mutations R952H 
and R1049C as well as R1048W in human KCC2 were associated with autism (Merner et al, 
2015). 
 
Several phosphorylated residues have been identified in KCC2: serines 728 and 940 (S728; 
S940) (Lee et al, 2010, Lee et al, 2007), threonines 906 and 1007 (T906, T1007) (Rinehart et al, 
2009) and tyrosines 903 and 1087 (Y903 and Y1087) (Lee et al, 2010). In addition, several 
predicted sites of KCC2 phosphorylation have been identified (Payne et al, 1996, Weber et al, 
2014) (Fig. 4).  
 
The last 18 C-terminal amino acids in all CCCs are important for the interaction with brain-
type creatine kinase (CKB) (Inoue et al, 2004). KCC2 also interacts with the α2 subunit of the 
Na-K ATPase (K. Ikeda et al, 2004) and with the protein associated with Myc (PAM) 
(Garbarini and Delpire, 2008). KCC2 C-terminus contains a non-canonical di-leucine motif 
that interacts with the clathrin-binding adaptator protein-2 (AP-2) (Zhao et al, 2008). 
Moreover, KCC2 interacts with several synaptic proteins: GABAA receptors (Huang et al, 
2012), the GluK2 subunit of kainate receptors (Mahadevan et al, 2014) and its interacting 
protein Neto2 (Ivakine et al, 2013). KCC2 through its C-terminal domain also interacts with 
actin related proteins 4.1N (Li et al, 2007) and Beta-PIX (Llano et al, 2015).  
 
The N-terminal part of KCCs is highly variable and often subject to alternative splicing, as 
in KCC2 (Uvarov et al, 2007). Truncation of the N-terminus of KCC2 has been shown to 
inhibit the ion-transport function (Li et al, 2007) and surface expression (Friedel et al, 2017). 
KCC2a and KCC2b, however have similar ion-transport properties when expressed in 
human embryonic kidney (HEK) cells (Uvarov et al, 2007). The SPAK binding sequence 
RFx(V/I) is present in N-terminal domains of several CCC family isoforms (Delpire and 
Gagnon, 2008, Richardson et al, 2008) and SPAK has been identified as a binding partner of 
all CCCs (Piechotta et al, 2002). In KCC2, the a-isoform specific N-terminal part contains a 
SPAK binding sequence and SPAK was also shown to interact with KCC2a (Uvarov et al, 
2009). Several residues have been shown to be directly phosphorylated by the SPAK kinase: 
T6 (a-isoform specific) T77, S78, S83, T92, and T1007 (de Los Heros et al, 2014). 
 
CCCs are suggested to exist as functional homo- or heterodimers in the plasma membrane 
(Medina et al, 2014). KCC2 proteins are also demonstrated to exist as functional oligomers in 
the plasma membrane (Blaesse et al, 2006) and KCC2a and KCC2b may also form heteromers 
in vivo (Uvarov et al, 2009). However, it is not clear how oligomerization affects ion-transport 
activity, or what the functional relevance of heterodimers is. Recently KCC2 was found to 
exist as monomers and dimers in the plasma membrane when overexpressed in HEK293 
cells, and no higher oligomers or aggregates were observed in Native PAGE experiments 
(Agez et al, 2017). Moreover, both the KCC2 monomers and dimers were functional. Based 
on electron microscopy analysis, a 3-D model was suggested where asymmetrical KCC2 
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dimers are formed via functional homodimerization of the C-terminal domain while disulfide 
bridges also are important in dimerization (Agez et al, 2017).  
 
KCC2 in the plasma membrane is internalized and recycled back to the plasma membrane 
through constitutive endocytosis mediated by dynamin and clathrin in HEK293 cells (Zhao 
et al, 2008). In addition, PACSIN1 was found to exist in a complex with KCC2 in mouse 
brain (Mahadevan et al, 2017). PACSIN1 is an endocytic adapter protein that plays important 
roles in postsynaptic receptor recycling. A half-time turnover rate close to 10 min was 
estimated for KCC2 under basal conditions (Rivera et al, 2004, Lee et al, 2007, Zhao et al, 
2008, Lee et al, 2010) but was estimated to be several hours or days in another study using 
brain slices (Puskarjov et al, 2012). The C-terminal domain also contains two predicted PEST 
(Proline/E (glutamate)/Serine/Threonine) sequences that are unique to KCC2 and 
suggested to function in targeting proteins for rapid degradation (Mercado et al, 2006). 
 
The expression and function of KCC2 at the membrane is regulated by multiple pathways 
via various post-translational modifications. Rapid internalization of KCC2 is seen following 
an increase in neuronal or synaptic activity (Chamma et al, 2013, Fiumelli et al, 2005, Watanabe 
et al, 2009, Lee et al, 2011, Kahle et al, 2013). Activity-induced dephosphorylation of Ser940 
and phosphorylation of Tyr903/1087 leads to increased endocytosis of KCC2 (Lee et al, 2010, 
Lee et al, 2011). Ca2+ influx through N-methyl-D-aspartate receptors (NMDARs) leads to a 
calcium dependent Ser940 dephosphorylation and resulted in calpain-mediated cleavage of 
the C-terminal domain and KCC2 internalization (Puskarjov et al, 2012, Chamma et al, 2013). 
The interaction between KCC2 and the endocytic regulatory protein PACSIN1 restricts the 
expression and activity of KCC2 in hippocampal neurons (Mahadevan et al, 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Topology model of the KCC2 protein 
The model represents the mammalian KCC2 protein, and N-terminal parts of both 
isoforms (KCC2a and KCC2b) are shown. Functional domains as well as domains for 
protein-protein interactions are indicated. Phosphorylated residues and predicted 
phosphorylation sites, as well as residues involved in turnover (surface stability and/or 
internalization mechanism), ion-transport function and possible structural interactions are 
also shown. Numbering is according to KCC2a in the N-terminal part (in red), otherwise 
numbering corresponds to the KCC2b sequence. 
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1.3.2 Protein expression  
 
In Western blot analysis with antibody against the KCC2b isoform, the KCC2b protein 
expression in mouse brain is characterized by an increase during development, similar to what 
is observed at the mRNA level (Stein et al, 2004). In mouse spinal cord and brainstem, KCC2b 
signals were intense already at E15.5 and did not further increase beyond P3. In mouse 
cerebellum and cortex KCC2b was first detectable at E15.5 and in hippocampus at P3. A 
strong KCC2b protein upregulation was observed in cerebellum, hippocampus, and cortex 
between E15.5 and P15 (Stein et al, 2004).  
 
Western blot analysis with antibody against the KCC2a isoform has demonstrated that 
KCC2a expression changes only moderately during postnatal mouse development (Uvarov 
et al, 2009). KCC2a protein levels between P2 and adult time-points were about 2-fold 
decreased in brainstem and spinal cord and 2-fold higher in cortex. Total KCC2 (KCC2pan 
antibody recognizing both isoforms) protein levels between P2 and adult time-points was not 
increased in the spinal cord, increased 2-fold in the brainstem and approximately 15-fold in 
the cortex.  
 
At P2, KCC2a contributes approximately half of the total KCC2 in mouse CNS (in 
brainstem, cortex and spinal cord). KCC2a expression in the P2 brainstem and spinal cord 
was similar and 3-fold higher than expression in the P2 cortex (Uvarov et al, 2009). In adult 
mouse, KCC2b is the prevalent isoform: the percentage of KCC2a of the total KCC2 is 4% 
in the cerebellum, 8% in the cortex, 10% in the hippocampus, 11% in the olfactory bulb and 
17–18% in the brainstem and spinal cord (Uvarov et al, 2009). The amount of the KCC2 
protein isoforms in neonatal and adult mouse reflects well their mRNA levels (Uvarov et al, 
2007). 
 
Using immunohistochemistry, the KCC2b protein was detected mainly in non-cortical 
regions in rat brain at P4: the olfactory bulb, the rostrodorsal region of the caudate–putamen, 
thalamus and hypothalamus, the superior and inferior colliculus, the pons, and the medulla. 
KCC2b protein expression was weak in hippocampus and cortex but some expression was 
detected in dorsocaudal regions of cortex. In the cerebellum, only ventrocaudal regions 
demonstrated some KCC2b expression at P4 (Blaesse et al, 2006). At P12, KCC2b protein 
expression was detected at a rather uniform level throughout the brain. In the regions 
displaying a high KCC2b expression already at P4, there was no additional increase in the 
signal, whereas in regions with weak KCC2b expression at P4 (hippocampus and most parts 
of the neocortex and cerebellum), the signal increased until P12 (Blaesse et al, 2006).  
 
A similar cellular distribution of KCC2 isoforms was observed by immunohistochemistry in 
E18 mouse brain (Uvarov et al, 2009). KCC2a and KCC2b immunoreactivities were seen in 
non-cortical regions (including olfactory bulb, basal forebrain, hypothalamus, thalamus, 
midbrain, and hindbrain), whereas labeling of cerebral cortex and hippocampus was close to 
the background level. Most neurons in non-cortical brain structures were positive for both 
KCC2a and KCC2b, although the relative expression of the two isoforms showed some 
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regional variability. In E18 midbrain double-stained with the KCC2a and KCC2b specific 
antibodies, most positive neurons were observed to co-express KCC2a and KCC2b (Uvarov 
et al, 2009).  
 
 
1.3.3 Subcellular localization 
 
In light and electron microscopic studies of mature CNS neurons, KCC2 immunoreactivity 
is mainly found associated with the plasma membrane in somatic and dendritic 
compartments. This distribution has been observed in many neuronal cells using antibodies 
detecting both isoforms, for example in hippocampal pyramidal cells of rat (Gulyas et al, 2001, 
Baldi et al, 2010), in neurons of the substantia nigra pars reticulata (Gulacsi et al, 2003), in 
thalamic relay cells (Bartho et al, 2004), in mature pyramidal cortical neurons of rat (Szabadics 
et al, 2006),  in mouse cerebellar granule cells (Takayama and Inoue, 2006) and in neurons of 
the suprachiasmatic nucleus of rat (Belenky et al, 2008). Similarly, KCC2b isoform 
immunoreactivity is also clearly concentrated at the plasma membrane of somas and 
dendrites in spinal motoneurons (Hubner et al, 2001, Boulenguez et al, 2010, Stil et al, 2011) 
and in brainstem auditory neurons (Blaesse et al, 2006). 
 
In thalamic relay cells, the density of KCC2 immunoreactivity was relatively even in the 
various soma-dendritic compartments and did not correlate with dendritic diameter or 
synaptic coverage (Bartho et al, 2004). Both proximal parts of dendrites as well as distal parts 
were labeled in the cerebellar granule cells of adult mouse (Takayama and Inoue, 2006). In 
hippocampal principal neurons of rat, cell type-specific distribution profiles of KCC2 within 
the dendritic tree were observed: Dendrites of dentate granule cells showed higher KCC2 
concentration compared with the soma, but the dendritic distribution was relatively 
homogeneous. In CA1 pyramidal cells, highest KCC2 density was found in the proximal 
apical and basal dendrites followed by the somatic membrane, while dendritic region-specific 
differences were detected between proximal and distal dendrites (Baldi et al, 2010). 
 
KCC2 is not detected in axons (Baldi et al, 2010, Szabadics et al, 2006, Hubner et al, 2001). In 
pyramidal cortical neurons of rat, absence of KCC2 at the axon initial segment was 
demonstrated as well as a decrease of KCC2 density in the plasma membrane from somatic 
to axon initial segment (Szabadics et al, 2006). In hippocampal principal neurons of rat, the 
axon initial segment contained very little of KCC2 and the density of KCC2 increases through 
the somata and towards the dendrites (Baldi et al, 2010). 
 
While KCC2 labeling is predominantly observed at the plasma membrane in mature neurons, 
only little cytoplasmic staining is detected, for example in hippocampal pyramidal cells 
(Gulyas et al, 2001), in neurons of the cochlear nucleus (Vale et al, 2005) and neocortex 
(Szabadics et al, 2006). In the cerebellar granule cells of adult mouse, the cytoplasm, Golgi 
apparatus and endoplasmic reticulum did not show KCC2 labeling (Takayama and Inoue, 
2006). In neurons of the suprachiasmatic nucleus, organelles including Golgi apparatus and 
endoplasmic reticulum occasionally showed KCC2 staining (Belenky et al, 2008). In neurons 
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of the substantia nigra pars reticulata, transport vesicles immunoreactive for KCC2 were 
occasionally observed in the cytoplasm of dendrites (Gulacsi et al, 2003).  
 
In immature neurons, intracellular KCC2 labeling is typically found at a higher level, for 
example in hippocampal neurons at P2 (Gulyas et al, 2001), where KCC2 is seen at the 
membrane of transport vesicles in dendrites. However, the KCC2b isoform protein was 
present along the plasma membrane of somata and dendrites in spinal cord motoneurons 
already at E18.5 similar to adult (Hubner et al, 2001). The KCC2b protein was also present 
at the plasma membrane in early postnatal brainstem auditory neurons (Blaesse et al, 2006). 
 
Accumulation of KCC2 was observed in the vicinity of excitatory synapses in hippocampus 
and in thalamic relay nuclei (Gulyas et al, 2001, Bartho et al, 2004). In pyramidal neurons of 
the hippocampus, KCC2 is significantly enriched within dendritic spines (Gulyas et al, 2001). 
KCC2 is also seen near excitatory synapses formed by cerebellar mossy fiber terminals onto 
granule cells (Takayama and Inoue, 2006). 
 
KCC2 is also observed near symmetrical inhibitory synapses in neurons of the substantia 
nigra pars reticulata (Gulacsi et al, 2003) and the suprachiasmatic nucleus (Belenky et al, 2008) 
where KCC2 was observed to colocalize with GABA type A receptors. The distribution 
profile of KCC2 along apical dendrites in rat hippocampal CA1 neurons correlated well with 
the distribution of GABAergic synapses (Baldi et al, 2010).  
 
The KCC2b isoform was also enriched near inhibitory synapses in adult spinal motoneurons 
and colocalized with gephyrin, a postsynaptic protein involved in the clustering of glycine 
and GABAA receptors (Hubner et al, 2001). In neurons of the auditory branstem KCC2b 
was observed both near excitatory and inhibitory synapses (Blaesse et al, 2006).  
 
In immunostainings, KCC2 in several studies shows a punctate distribution at the plasma 
membrane (Blaesse et al, 2006, Gulyas et al, 2001, Belenky et al, 2008), and this was suggested 
to correspond to functional tyrosine-phosphorylated KCC2 localized in lipid raft 
microdomains in cultured rat hippocampal neurons (Watanabe et al, 2009). Similarly, KCC2 
immunoreactivity in mature rat brain was localized both to membrane rafts and non-raft 
domains (Hartmann et al, 2009). In neonatal rat brainstem, KCC2 largely partitioned into 
membrane rafts and was found to be in an inactive form, while an increase in KCC2 
clustering and transport activity was observed in the absence of lipid rafts (Hartmann et al, 
2009). 
 
 
 
1.3.4 Functional roles of KCC2 isoforms  
 
KCC2 function determines the efficacy and polarity of the chloride-permeable GABA type 
A and glycine receptor mediated synaptic transmission. Early in development, the expression 
and activity of KCC2 in neurons is low relative to NKCC1, resulting in a high intracellular 
Cl- concentration and depolarizing responses to GABA and glycine. As neurons mature, 
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KCC2 expression and activity is upregulated, resulting in a reversal of the Cl– electrochemical 
potential in neurons and GABA and glycine responses become hyperpolarizing (Rivera et al, 
1999).  
 
In several areas of neonatal mouse brain, KCC2 protein expression levels appear high but 
responses to GABA are still depolarizing (Khirug et al, 2010). KCC2 seems to be transport-
inactive in early development for example in neonatal brainstem neurons (Blaesse et al, 2006, 
Balakrishnan et al, 2003), and in immature hippocampal neurons (Khirug et al 2005). The 
functional activation of KCC2 in development is suggested to involve transport to the plasma 
membrane, oligomerization, phosphorylation/dephosphorylation or other protein 
modifications (Blaesse et al, 2006, Zhang et al, 2006, Khirug et al, 2005, Friedel et al, 2015). 
 
KCC2 null mutant mice that completely lack both KCC2 isoforms show a disrupted 
breathing rhythm and die immediately after birth (Hubner et al, 2001, Tornberg et al, 2005). 
The respiratory failure is due to a disrupted inspiratory-related rhythmic motor output of the 
brainstem pre-Bötzinger complex (Hubner et al, 2001). Motoneurons of the spinal cord also 
showed an excitatory response to GABA or glycine, whereas in wild-type mice of the same 
age an inhibitory response was observed. Expression of KCC2 mRNA and protein is high in 
mouse brainstem and spinal cord neurons already at birth (Hubner et al, 2001, Balakrishnan 
et al, 2003) and the function of KCC2 in these brain regions thus seems to be important 
already at birth.  
KCC2 hypomorph mice, which express only about 20% of KCC2 are viable and fertile and 
have normal locomotor activity and motor coordination but exhibit a growth deficit and 
increased anxiety-like behavior (Tornberg et al, 2005). 
 
Selective KCC2b isoform knock-out mice, in which the KCC2b isoform has been disrupted 
leaving the expression of the KCC2a isoform untouched, can survive up to three weeks after 
birth (Woo et al, 2002). These mice appear normal at birth but demonstrated abnormal 
posture and gait and frequent spontaneous seizures within a couple of days after birth that 
ultimately led to their deaths (P12–P17). The KCC2a expression in the brain and spinal cord 
(~50% of total KCC2 in newborn mice) is thus presumably enough to allow the mice to 
bypass the lethality observed with full KCC2 KO mice at birth.  
 
Recordings from KCC2b KO mice neurons have confirmed the important role of the 
KCC2b isoform for chloride homeostasis: In dissociated cortical neurons derived from 
KCC2b-deficient mice, no significant decrease in the intracellular chloride concentration was 
observed after three weeks in culture in contrast to wild-type neurons (Zhu et al, 2005). 
Neonatal spinal motoneurons of KCC2b-deficient mice (Stil et al, 2011) demonstrated a more 
depolarized glycine reversal potential similar to that found in motoneurons of KCC2 null 
mice (Hubner et al, 2001).  
Cultured cortical neurons from KCC2 null mice demonstrate long filopodia-like spines and 
a reduced number of functional excitatory synapses and reduced mEPSC frequency (Li et al, 
2007). Spine maturation could be rescued by expression of a non-functional, N-terminal 
deficient KCC2 and mimicked by expression of the KCC2 C-terminal domain (Li et al, 2007). 
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Since the KCC2 C-terminal region interacts with protein 4.1N which is an actin-interacting 
protein important in cytoskeletal organization at synapses, this interaction may contribute to 
maturation of spines (Li et al, 2007). Supporting this, premature expression of KCC2 in 
mouse cortex induces an increase in spinogenesis and excitatory synapse density in vivo 
(Fiumelli et al, 2013). It has also been shown that the KCC2 interaction with 4.1N is important 
for the plasticity of AMPA receptors in mature neurons and thus for the basal excitatory 
activity at mature cortical excitatory synapses (Gauvain et al, 2011).  
 
Hippocampal networks in KCC2 null mice demonstrate changes in activity, hyperexcitability 
and generate spontaneous seizure activity at E18.5 (Khalilov et al, 2011). More GABAergic 
and glutamatergic synapses and currents were also observed in the KCC2 null embryos 
compared to wild-type embryos. However, KCC2 was not functional as a transporter at this 
time-point, as no significant difference in the intracellular Cl- concentration was observed 
between hippocampal neurons from KCC null and wild type mice. These results thus suggest 
that a transport-unrelated functions of KCC2 are important already at embryonic stages 
(Khalilov et al, 2011). 
 
In cortical structures KCC2 labeling is first detected at the end of embryonic development 
and peaks during the second postnatal week (Blaesse et al, 2006, Stein et al, 2004). Pyramidal 
cortical neurons show very little KCC2 expression at birth and during the first postnatal 
week. However, in the developing mouse cortex, in a subset of tangentially migrating 
interneurons, KCC2 has been detected already at the time of birth, prior to synaptogenesis 
(Bortone and Polleux, 2009). When KCC2 is upregulated in these neurons, the ambient 
GABA mediated depolarization becomes hyperpolarizing, acting as a stop signal for the 
interneurons, leading to termination of migration (Bortone and Polleux, 2009). 
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1.4 THE WNK–SPAK/OSR1 PATHWAY 
 
Ion transport mediated by CCCs across the cell surface is accompanied by water flux and 
thus CCCs also participate in maintaining water homeostasis (osmoregulation) (MacAulay et 
al, 2004).  WNK kinases (With No lysine =K) and their downstream kinases SPAK/OSR1 
of the Ste20- family are serine-threonine kinases and key regulators of CCCs in response to 
osmotic challenges (Kahle et al, 2010, Alessi et al, 2014). It has also been shown that the 
WNK-SPAK/OSR1 pathway is directly regulated by intracellular Cl- as the activation of 
WNKs is prevented when Cl- binds to the active site and stabilizes the inactive conformation 
(Piala et al, 2014).  
 
Exposure of HEK293 cells to conditions that activate the WNK signalling pathway resulted 
in increased phosphorylation of KCCs, WNK1, SPAK/OSR1 and NKCC1, while conditions 
that inhibit the WNK signalling pathway induced a rapid dephosporylation of the same 
molecules (de Los Heros et al, 2014).  
 
Stimuli such as extracellular hyperosmotic challenge or intracellular chloride decrease leads 
to activation of the WNK–SPAK/OSR1 pathway and results in serine/threonine 
phosphorylation of CCCs. Phosphorylation of CCCs via WNK–SPAK/OSR1 pathway 
activates the transport function of N(K)CCs and inhibits that of KCCs. Activity of N(K)CCs 
results in a net influx of chloride and water that compensates for cell shrinking and results in 
a regulatory volume increase. On the other hand, hypoosmotic challenge, hypotonic high K+ 
conditions or a rise in internal chloride concentration results in inhibition of the WNK–
SPAK/OSR1 pathway and dephosphorylation of CCCs. Dephosphorylation inhibits 
N(K)CCs and activates KCCs and results in a net efflux of chloride and water and a regulatory 
volume decrease acting to compensate cell swelling (Alessi et al, 2014).  
 
In response to activated WNK-SPAK/OSR1 pathway KCC2 is phosphorylated at T906 
(termed site1) and T1007 (termed site2) in the C-terminal domain (Rinehart et al, 2009). When 
overexpressed in HEK293 cells, KCC2 is robustly phosphorylated at Thr906 and Thr1007 
and dephosphorylation of these sites significantly stimulates KCC2 activity (Rinehart et al, 
2009, de Los Heros et al, 2014). Dual dephosphorylation of KCC2 at Thr906 and Thr1007 
also strongly stimulates KCC2 activity in neurons (Kahle et al, 2013, Friedel et al, 2015). Site1 
and site2 are conserved in all KCCs and the phosphorylation/dephosphorylation has similar 
effects on all KCCs (Rinehart et al., 2009). SPAK and OSR1 are known to directly 
phosphorylate site2 of KCCs, but they may not phosphorylate directly site1 (de Los Heros et 
al, 2014).  
 
In addition to site2, multiple other serine (S78, S83) and threonine (T6, T77, T92) residues 
in the KCC2a isoform have been shown to be directly phosphorylated by SPAK kinase in 
vitro (de Los Heros et al, 2014). All of these sites except T6, which is located in the KCC2a 
isoform specific N-terminal part, are also present in the KCC2b isoform (see Fig 4). 
Moreover, the T6 site was found to be conserved in all KCCs except the KCC3A isoform 
(de Los Heros et al, 2014). 
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KCC-mediated ion transport is induced by cell swelling and downregulated at low 
intracellular Cl− concentration (Adragna et al, 2004, Lytle and McManus, 2002). When 
expressed in Xenopus oocytes, KCC1, KCC3, and KCC4 express minimal activity in isotonic 
conditions but are strongly activated by cell swelling induced by hypotonic conditions 
(Mercado et al, 2000). KCC2 was found to be functional at isotonic conditions when 
expressed in Xenopus oocytes and exhibited minimal activation by cell swelling (Strange et 
al, 2000), likely due to the ISO domain (Mercado et al, 2006). However, the transport activity 
of human KCC2 overexpressed in Xenopus laevis oocytes was stimulated by cell swelling 
(Song et al, 2002). Activation of K+-Cl– cotransport by cell swelling has been ascribed to the 
inhibition of the WNK-SPAK/OSR1 kinases, combined with the activation of protein 
phosphatase 1 and 2A -dependent dephosphorylation (Kahle et al, 2015). 
 
The members of WNK family have been shown to inhibit the activity of the KCC2 
cotransporter exogenously overexpressed in Xenopus oocytes (de Los et al, 2006, Gagnon et 
al, 2006, Rinehart et al, 2011). The transport function of KCC2 was diminished by the 
expression of SPAK and WNK4 under both isosmotic and hyposmotic conditions (Gagnon 
et al, 2006). WNK1 inhibited the activity of all mammalian KCCs (KCC1, KCC2a, KCC2b, 
KCC3a, KCC3b, and KCC4) when coexpressed in Xenopus oocytes (Mercado et al, 2016).  
 
KCC3 is expressed in multiple tissues, and knockout studies have revealed that it is important 
in volume regulation and particularly in neuronal volume regulation following hyposmotic 
swelling (Rust et al, 2006, Boettger et al, 2003, Byun and Delpire, 2007). In contrast, the 
primary physiological function of the constitutively active KCC2 is to maintain the low 
intracellular Cl- concentration of neurons in isotonic conditions. However, results suggest 
that KCC2 may also participate in osmotic and volume regulation in dendritic spines 
following isosmotic activity-induced neuronal swelling (consisting of an increase in the net 
influx of Na+, Cl− and osmotically obliged water) (MacAulay et al, 2004, Jourdain et al, 2011, 
Gauvain et al, 2011).  
 
The phosphorylation state of KCC2 is correlated with its functional activation during 
development (Khirug et al, 2005) and the WNK-kinase pathway might be involved in the 
developmental activation of KCC2. The KCC2 Thr906 and Thr1006 residues are 
phosphorylated at early stages of development and their dephosphorylation parallels the 
maturation of GABAergic transmission (Kahle et al, 2013, Rinehart et al, 2009). WNK1 
dependent phosphorylation of KCC2 in mature neurons causes a loss of transport function 
(Rinehart et al, 2009, Kahle et al, 2005). Thr-906 and Thr-1007 phosphorylation of KCC2 did 
not affect cell surface KCC2 expression of KCC2 (Rinehart et al, 2009). Overexpression of 
active WNK1 also resulted in KCC2 inhibition in cultured neurons (Inoue et al, 2012). 
Knockdown of WNK1 in immature neurons resulted in dephosphorylation of Thr906 and 
Thr1007 of KCC2 and significantly enhanced KCC2-dependent Cl− extrusion and caused a 
hyperpolarizing shift of the EGABA (Friedel et al, 2015). 
 
SPAK/OSR1 interact with RFx(V/I) motifs present in N-terminal domains of CCCs 
(Delpire and Gagnon, 2008, Richardson et al, 2008). The RFx(V/I) motif is present in N-
terminal domains of several CCC family isoforms; at least one splice variant of each 
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mammalian CCC family member, except KCC1, has the binding motif. The N-terminal 
domain of the KCC2a isoform contains this sequence, but it is not present in the KCC2b 
isoform (Uvarov et al, 2007). The motif is also found in N-termini of KCC2 orthologs in 
Drosophila (Hekmat-Scafe et al, 2006) and C. elegans (Tanis et al, 2009).  
 
RFx(V/I) motifs are also present on WNK isoforms and SPAK kinases are known to interact 
with WNK kinases through this motif (Piechotta et al, 2003). Elimination of the 
SPAK/OSR1binding site of WNK1 prevented the effect of WNK1 on KCCs suggesting that 
activation of WNK1 depends on the interaction with SPAK /OSR1 (Mercado et al, 2016).  
 
It has also been suggested that WNK kinases interact with each other by oligomerization, 
and the WNK-WNK interaction was necessary for the WNK1 inhibitory effect on KCCs 
(Mercado et al, 2016). KCC2 has also been shown to form a physical complex with WNK1 
kinase in the developing brain, and this interaction might function as a link between SPAK 
and KCC2 (Friedel et al, 2015).  
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2. AIMS OF THIS STUDY 
 
The general aim of this work was to elucidate the isoform-specific differences in the 
expression, function and regulation of the KCC2 isoforms. More specific goals were to study 
the following: 
 
 
 
1. The involvement of transcription factors USF1 and USF2 in the KCC2b 
transcriptional regulation via the E-box motif. 
 
 
2. The expression patterns and subcellular localization of the KCC2a and KCC2b 
isoforms in mouse CNS using immunohistochemistry. 
 
 
3. The functionality of the KCC2a isoform as a chloride cotransporter in neurons. 
 
 
4. The binding and functional regulation of the KCC2 isoforms by SPAK. 
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3. MATERIALS AND METHODS 
 
The experimental methods used in this work are listed in Table I with a reference to the 
appropriate original publication where detailed descriptions can be found. Transgenic mice 
are listed in Table II and expression constructs are listed in Table III. Primary antibodies are 
discussed in section 3.1, and listed in Table IV.  
 
 
 
Table I. Methods used and described in the original articles 
Method Used in 
Western blotting (WB) I,II,III 
Electrophoretic mobility shift assay (EMSA) I 
Chromatin immunoprecipitation assay (ChIP) I 
Cell culture I,II, III 
Transfection II, III 
Animals and tissue processing II, III 
Immunohistochemistry (IHC) II,III 
In situ hybridization (ISH) II 
Microscopy, imaging II, III 
Immunocytochemistry (ICC) III 
Electrophysiological recordings III 
Calcium imaging III 
Biotinylation assay III 
Coimmunoprecipitation assay (coIP) III 
Functional 86Rb flux assay III 
 
 
 
 
Table II. Transgenic Mice 
Strain Description Source/Reference Used 
in 
KCC2null Knock-out mice that lack 
both KCC2 isoforms 
(Tornberg et al, 2005)  II,III 
KCC2a-KO Selective KCC2a isoform 
knock-out mice 
Study II II 
KCC2b-KO Selective KCC2b isoform 
knock-out mice 
(Woo et al, 2002) III 
 
 
 
 
 
 
 
23 
 
Table III. Plasmid constructs 
Construct Description Source/Reference Used 
in 
KCC2b(0.6) 0.6 kb KCC2 promoter fragment in pGL3-
Basic (Promega) firefly luciferase reporter 
vector. 
Study I I 
E-box mut KCC2b(0.6) construct with a mutation in the 
E-box motif 
Study I I 
A-USF USF dominant-negative mutant in modified 
CMV566 expression vector 
Dr. Charles Vinson 
 (Qyang et al, 1999) 
I 
KCC2a Full-length rat KCC2a cDNA in pcDNA3.1 
(Invitrogen) expression vector 
(Uvarov et al, 2007) III 
KCC2b Full-length rat KCC2b cDNA in pcDNA3.1 
(Invitrogen) expression vector 
(Uvarov et al, 2007) III 
HA-SPAK Hemagglutinin (HA) –tagged SPAK Dr. Forbush 
(Dowd and 
Forbush, 2003) 
III 
DNSPAK Dominant negative, kinase-inactive K101R 
form of SPAK 
Dr. Forbush 
(Dowd and 
Forbush, 2003) 
III 
 
 
 
3.1 PRIMARY ANTIBODIES 
 
The KCC2a antiserum was raised in rabbit against a 21 -amino acid peptide corresponding 
to the N-terminus of the mouse KCC2a sequence (amino acids 20-40) (Uvarov et al, 2009) 
(Fig. 5). The specificity of the anti-KCC2a antiserum was tested in Western blot and 
immunohistochemistry using neonatal wild-type and KCC2null mutant mice (Uvarov et al, 
2009). The antibody produced a high background in immunostainings of mouse brain 
cryosections when using 4% paraformaldehyde (PFA) fixation, but the background was 
significantly decreased when using cold methanol-acetone (1:1) fixation (Uvarov et al, 2009). 
The KCC2a antiserum was also tested in immunocytochemistry with hippocampal neurons 
derived from E17 wild-type and KCC2 null KO mice embryos (Uvarov et al, 2009), and the 
antiserum produced a specific staining when using methanol-fixation of the cells. 
 
In study II we set out to optimize the immunostaining method with the KCC2a antiserum 
and PFA-fixed tissue. Prior to use in immunostainings, the KCC2a antiserum was 
preabsorbed against PFA-fixed tissue from KCC2a-KO mice. This helped to reduce the 
background signal in immunostainings with PFA-fixed adult mouse brain sections (Study II, 
Fig 1). Moreover, shorter post-fixation time with 4% PFA (30 minutes or 2 hours at most) 
also reduced the nonspecific signal. Preabsorbed antiserum and short post-fixation time was 
thus used with PFA-fixed adult mouse sections in study II and study III. Preabsorption was 
less efficient at removing the background staining from PFA-fixed young postnatal mouse 
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brain sections in KCC2a immunohistochemistry, thus methanol–acetone post-fixation was 
used for the earlier time points in study II.  
 
The KCC2b antiserum was raised in rabbit against a 15-amino-acid peptide corresponding 
to the N-terminus of the KCC2b isoform (amino acids 8-22) (Hubner et al, 2001) (Fig. 5). 
The last five amino acids in this peptide are common to both KCC2 isoforms, but the 
antibody is highly specific for the KCC2b isoform (Uvarov et al, 2009). In study II we 
generated KCC2b antibodies against the same peptide in chicken, and the specificity of the 
antibodies was tested in Western blot using brain lysates from wild-type and KCC2 null mice 
(Study II, Fig. 2). 
 
The KCC2-pan antiserum was generated in rabbit against a C-terminal peptide of rat KCC2 
(amino acids 932–1043), corresponding to a region that is highly variable among KCCs 
(Williams et al, 1999, Ludwig et al, 2003) (Fig. 5). The specificity of the antibody has been 
tested using wild-type and KCC2 null mice brain homogenates in Western blot analysis 
(Ludwig et al, 2003), and in immunohistochemistry (Uvarov et al, 2009). A monoclonal mouse 
KCC2pan antibody against the same C-terminal peptide of rat KCC2 has also been generated 
(Chemicon /Millipore), the antibody was tested in immunohistochemistry in study II, and it 
produced an identical staining pattern as the rabbit KCC2pan antibody. 
 
 
 
Table IV. Primary antibodies used in this work 
Against Host Source/Reference Methods Used 
in 
USF1 Rb Santa Cruz EMSA, ChIP I 
USF2 Rb Santa Cruz WB, EMSA, 
ChIP 
I 
Egr4 Rb (Zipfel et al, 1997) EMSA I 
KCC2a Rb (Uvarov et al, 2009) WB, IHC II, III 
KCC2b Ch study II WB, IHC II, III 
KCC2b Rb (Uvarov et al, 2009, Hubner et al, 2001) IHC II 
KCC2pan Rb  (Williams et al, 1999, Ludwig et al, 2003) WB, IHC,  II, III 
KCC2pan  Ms Chemicon /Millipore  IHC II 
MAP2 Ms Chemicon /Millipore IHC II 
SPAK Rb (Ushiro et al, 1998) WB, coIP III 
β-tubulin Ms BabCO WB III 
HA Ms GE Healthcare WB, coIP III 
Ch (chicken), Ms (mouse), Rb (rabbit), MAP2 (microtubule-associated protein 2), HA 
(hemagglutinin) 
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Fig. 5. KCC2 antibodies 
Shown are the peptides against which selected KCC2 antibodies have been generated. 
The KCC2a antiserum was raised against a 21 -amino acid long peptide in the KCC2a 
isoform specific N-terminal part. KCC2b antibodies have been generated in rabbit and 
chicken against a 15-amino acid long sequence in the N-terminal part of the KCC2b 
isoform. Five amino acids of this peptide belong to the part of N-terminus that is common 
to both isoforms. KCC2pan antiserum was generated in rabbit against a 112-amino acid 
long segment in the common C-terminal part of KCC2, and the KCC2pan antibodies thus 
detect both KCC2 isoforms.  
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4. RESULTS AND DISCUSSION 
 
 
4.1 REGULATION OF KCC2B EXPRESSION BY USF PROTEINS 
 
Sequence analysis of the mouse KCC2b promoter region showed that the -319 to -314 -
region contained an E-box consensus element (CACGTG) (Uvarov et al, 2006). The E-box 
element was conserved in the mouse, rat, human and chimpanzee KCC2b promoters. The 
E-box element is a hexanucleotide sequence (CANNTG) recognized by the basic helix-loop-
helix (bHLH) family of transcription factors (Jones, 2004). Many bHLH proteins bind 
strongly to the CG dinucleotide containing palindromic E-box CACGTG.  
 
Members of the bHLH family are found in almost all eukaryotes (Jones, 2004). The bHLH 
domain comprises a DNA-binding basic region (b) and a helix-loop-helix (HLH) motif, 
which is involved in homo- and hetero- dimerization with other HLH proteins. The two 
basic domains brought together through dimerization bind the transcription factor to DNA 
and each monomer of the bHLH dimer binds a CAN half-site. A number of bHLH protein 
families have a leucine-zipper domain that also mediates dimerization in addition to the HLH 
motif (Jones, 2004).  
 
Upstream stimulating factors 1 (USF1) and 2 (USF2) are bHLH/leucine zipper transcription 
factors that bind to E-box elements (Sirito et al, 1994). USFs were initially identified as a 
cellular transcription factor for the adenovirus-2 major late gene (Carthew et al, 1985, Moncollin 
et al, 1986, Sawadogo and Roeder, 1985). USFs normally bind as USF1/USF2 heterodimers 
to the E-box element and are involved in transcriptional activation. Both USF1 and USF2 
transcription factors are ubiquitously expressed in animal tissues (Sirito et al, 1994, Sirito et al, 
1998) but the expression level in brain is particularly high (Fujimori and Urade, 2007, Park 
and Russo, 2008). USFs normally bind to the palindromic consensus E-box sequence, 
CACGTG (Sawadogo and Roeder, 1985). Electrophoretic mobility shift assay (EMSA) and 
supershift experiments have indicated that USF proteins are the major binding factors for 
the palindromic CACGTG E-box motif in mouse brain (Yamanaka et al, 2016).  
 
A large number of USF target genes has been identified, and include many genes important 
for fatty acid synthesis and insulin signaling (Corre and Galibert, 2005, Rada-Iglesias et al, 
2008). The complete knockout of USF1 and USF2 induces embryonic lethality, 
demonstrating the requirement of USFs during embryogenesis (Sirito et al, 1998) . The 
knockout of USF2 suppresses glucose-dependent gene expression in mouse liver (Vallet et al, 
1997), and USF1 has been associated with familial combined hyperlipidemia (Pajukanta et al, 
2004).  
 
USFs also play essential roles in normal brain function: Both USF1 and USF2 knockout mice 
display a propensity for spontaneous epileptic seizures (Sirito et al, 1998). USFs have also 
been shown to regulate the expression of several neuronal genes, for example, fragile X 
mental retardation 1 (FMR1) (Kumari and Usdin, 2001), BDNF (Chen et al, 2003, Tabuchi et 
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al, 2002) amyloid precursor protein (Hoffman and Chernak, 1995),  GABA B1 receptor 
(Steiger et al, 2004), and prodynorphin (Bazov et al, 2017). 
 
In study I, we used EMSA and supershift assay with specific antibodies to USF1 and USF2, 
in order to determine if USF proteins associated with the E-box element of the KCC2b 
promoter in vitro (Study I, Fig 1). Our results showed that USF1 and USF2 proteins 
specifically bound to the E-box of KCC2b in vitro when using nuclear protein lysates of both 
mouse neuroblastoma N2a cells and NIH3T3 fibroblasts. The supershift assay demonstrated, 
that USF1/USF2 heterodimers appeared to form the major E-box binding complex in our 
experiment.  
 
Subsequently, the functional role of the E-box motif and USF transcription factors were 
examined in neuroblastoma N2a and NIH3T3 cells using a luciferase reporter assay (Study I, 
Fig 2). Cells were transiently transfected with a luciferase reporter construct containing a 0.6 
kb KCC2b promoter fragment (KCC2b(0.6)). Mutation of the E-box element in the KCC2b 
promoter (E-box mut construct) reduced the activity of the KCC2b promoter, suggesting 
that the E-box element is involved in basal KCC2b gene expression. Co-transfection with a 
dominant-negative form of USF (A-USF) was used in order to confirm the involvement of 
endogenous USF proteins in the regulation of the KCC2b gene. The A-USF functions by 
specifically dimerizing with USF1 and USF2 and preventing their binding to DNA (Qyang et 
al, 1999). Overexpression of A-USF resulted in supression of the KCC2b(0.6) reporter 
activity, indicating a contribution of endogenous USF proteins to expression driven by the 
KCC2b promoter in N2a and NIH3T3 cells. 
 
The role of the E-box motif of the KCC2b promoter, as well as binding of the USFs, was 
also studied in neurons (Study I, Fig 3). Evidence that endogenous USF1 and USF2 bind the 
KCC2b promoter was provided by chromatin immunoprecipitation assay (ChIP) in rat 
primary cortical neurons (8 DIV). The role of the E-box motif was also examined in a 
luciferase reporter assays in primary cortical cultures transfected with the KCC2b(0.6) 
construct. Mutation of the E-box element in the KCC2b promoter region (E-box mut 
construct) reduced the activity of the KCC2b promoter in 6 DIV cortical neurons by ~23%, 
but in 10 DIV cortical neurons, there was no significant change in promoter activity. The 
results suggested that the E-box element is involved in basal KCC2b gene expression in 
immature cortical neurons. 
 
The activity of USF proteins, such as DNA binding activity and transactivation effects, are 
modulated by many signaling cascades in cells (Galibert et al, 2001, Cheung et al, 1999, Nowak 
et al, 2005, Xiao et al, 2002). Post-translational modifications like phosphorylation have been 
shown to regulate the function of USFs, and USFs are phosphorylated by various kinases 
(Horbach et al, 2015). Among the protein kinases that phosphorylate USF1 are the cyclin 
dependent kinase cdk2, protein kinase A, phosphatidylinositol 3-kinase, DNA-dependent 
protein kinase (DNA-PK), stress activated kinase p38, and ERK1/2 kinase. Only a few 
kinases such as protein kinase A (PKA) and GSK3β are known to phosphorylate USF2 
(Horbach et al, 2015). 
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Interactions with other transcription factors or co-factors have also been shown to regulate 
the USF-dependent transactivation. Among the transcription factors and co-factors that have 
been described to interact with USFs are the b-Zip family protein Fra1 (Pognonec et al, 1997), 
the bHLH transcription factor Cha (Rodriguez et al, 2003), the hypoxia-inducible 
transcription factor HIF2α (Befani et al, 2013), the CCAAT/enhancer binding protein 
C/EBPβ (Dahle et al, 2002), and the homeodomain of the pancreatic transcription factor 
PDX-1 (Amemiya-Kudo et al, 2011).  
 
In neurons, USF proteins have been particularly linked to activity-dependent regulation of 
transcription by Ca2+-activated signaling pathways: A Ca2+-responsive composite E-
box/cAMP-responsive element (CRE) site was bound by USF1 and USF2 in the BDNF 
promoter I (Tabuchi et al, 2002), and in the BDNF promoter III a Ca2+-responsive E-box 
element (CaRE) was bound by USF1 and USF2 (Chen et al, 2003). USFs also bound to a 
depolarization-sensitive composite CREB/Activating transcription factor-4 (ATF4)/USF 
regulatory element in the GABA B1 receptor promoter (Steiger et al, 2004).  
 
An E box element bound by USFs in the rat preprotachykinin A promoter regulated the activity 
of this promoter in response to nerve growth factor (NGF) in dorsal root ganglion neurons 
(Gerrard et al, 2005). 
 
The expression level of USFs in brain is particularly high (Fujimori and Urade, 2007, Park 
and Russo, 2008), but the cellular expression pattern of USF1 and USF2 is not completely 
overlapping when studied in immunohistochemistry (Yamanaka et al, 2016): USF1 expression 
was strong in cortical neurons but relatively weak in hippocampus and striatal neurons, 
whereas USF2 was expressed in neurons of these brain regions to almost the same level. In 
another study, substantial cell-to-cell differences in USF2 expression were detected in the 
dorsolateral prefrontal cortex in immunohistochemistry (Bazov et al, 2017), and it was also 
reported that neurons and non-neuronal cells expressed USF2 at similar levels (Bazov et al, 
2017). 
 
The palindromic E-box motif (CACGTG) contains a potential CpG methylation site, and 
USFs have been identified as methylation-sensitive transcription factors (Griswold and Kim, 
2001).  Expression of the prodynorphin gene was associated with differential methylation of its 
promoter between neurons and glia (Bazov et al, 2017): The promoter was hypomethylated 
in neurons and hypermethylated in non-neuronal cells. USF2 bound to unmethylated E-box 
in the promoter of the prodynorphin gene, and activated gene transcription. Methylation of the 
E-box prevented the activation of prodynorphin transcription by USF2. In EMSA assay USF2 
bound to a nonmethylated E-box oligonucleotide with significantly higher affinity compared 
to a methylated E-box oligonucleotide (Bazov et al, 2017).  
 
Our results suggested that transcription factors binding to the E-box element in the KCC2b 
promoter participate in the basal KCC2b gene expression in immature neurons and could 
thus be involved in the developmental upregulation of KCC2b in vivo. Since the KCC2b 
promoter in rat primary cortical neurons at DIV8 was clearly occupied by USF1 and USF2 
in ChIP assay, this would suggest that USF1/USF2 heterodimers are involved in the 
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regulation of KCC2b via the E-box motif. This conclusion is also supported by our luciferase 
reporter assays in cell lines. However, as the binding and activity of USFs depends on various 
signalling pathways and interactions with other transcription factors or co-factors it is also 
possible that USFs participate in regulation of KCC2b transcription in response to yet 
unidentified conditions.  
 
USFs have been reported to function together with Ca2+ responsive transcription factors, 
such as CREB, in neurons (Chen et al, 2003, Steiger et al, 2004, Tabuchi et al, 2002), and this 
could be important also in the regulation of KCC2b. Activity- dependent influx of Ca2+ via 
voltage-gated calcium channels has been suggested as one mechanism of KCC2 upregulation 
in development (Ganguly et al, 2001). In mature hippocampal neurons, BDNF-TrkB 
signaling resulted in a down regulation of KCC2 gene expression via activation of the PLCγ 
pathway and the transcription factor CREB (Rivera et al, 2004). However, no binding sites 
for CREB or calcium-responsive transcription factor (CaRF) have been identified in the 
KCC2b promoter.  
 
Downregulation of KCC2 mRNA has been observed in epilepsy (Palma et al, 2006, Huberfeld 
et al, 2007) and sustained interictal-like activity resulted in a down regulation of KCC2 gene 
expression via the the BDNF-TrkB signaling cascade and CREB (Rivera et al, 2004, Rivera et 
al, 2002). Since both USF1 and USF2 knockout mice were prone to epileptic seizures (Sirito 
et al, 1998), decreased activity of USFs could be one putative mechanisms involved in the 
downregulation of KCC2b mRNA in epilepsy.  
 
In immature neurons, activation of TrkB by BDNF was shown to trigger only the Shc 
pathway resulting in the activation of a number of adaptor proteins and in the GTP-loading 
of Ras and subsequently to the activation of the mitogen-activated protein (MAP) kinase 
cascade. Sequential phosphorylation of Raf, Mek, and ERK, and translocation of ERK the 
nucleus. ERK1/2 activation resulted in the upregulation of KCC2 transcription via 
transcription factor Egr4 (Ludwig et al, 2011). ERK1/2 have also been shown to 
phosphorylate and activate USFs (Imagawa et al, 2006, Park and Russo, 2008). For example, 
in trigeminal ganglion neurons, USFs were found to be downstream targets of the MAP 
kinase and ERK pathway (Park and Russo, 2008). 
 
Since NRSE sites seem not to be critical for the neuron-specific expression of KCC2, it is 
possible that transcription factors binding to the KCC2b promoter region are sufficient to 
drive the neuron-specific expression of KCC2b mRNA (Uvarov et al, 2005). In line with this, 
the KCC2b promoter region contains several predicted binding sites for neuron-enriched 
transcription factors such as AP2, AP1, Mef2 and Egr4 (Uvarov et al, 2006). For example, 
Egr4 is highly enriched in neurons and has a similar temporal expression pattern (Uvarov et 
al, 2006). However, it has also been shown that USFs may direct neuron specific transcription 
even though they are ubiquitously expressed transcription factors (Bazov et al, 2017). The 
cellular environment is important in coordinating various cell-type specific functions of USFs 
and could be mediated by epigenetic factors, such as DNA methylation (Bazov et al, 2017). 
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As there are many E-box binding bHLH transcription factors, the effects of other bHLHs 
cannot be completely excluded. Several bHLH proteins are widely expressed in the CNS, for 
example c-Myc, Max, Neuro D. As binding and activity of USFs depends on interactions 
with other transcription factors, co-factors and the chromatin structure, other bHLH may 
associate with the E-box element of the KCCC2b promoter in another cellular context. A 
hypothetical model of the transcriptional regulation of KCC2b gene is presented in Fig. 7. 
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Fig. 6 Transcriptional regulation of KCC2b gene, a putative scenario. 
A. KCC2b gene promoter in non-neuronal or neural progenitor cells. The green DNA 
strand represents a CpG island with methylation (red dots). NRSF is bound to NRSE sites 
in the 5’ regulatory region of KCC2b and in intron 1b. Co-repressor complexes are 
associated with the NRSFs and participate in the covalent modification of chromatin. 
Activating transcription factors are unable to bind and initiate transcription. 
B. In immature neurons, in the absence of DNA methylation, activating transcription 
factors bind to the DNA elements in the KCC2b promoter region. USF1/USF2 
heterodimers and Egr4 are shown as well as other putative transcription factors (Sp1, 
AP2, AP1, Mef2). RNA polymerase II binds and initiates the transcription. ERK1/2 kinases 
as well as Ca2+-activated signaling pathways might be important in the upregulation of 
KCC2b transcription in development and could function in the activation of USF proteins, 
for example by stimulating their phosphorylation. 
C. In mature neurons, downregulation of KCC2b transcription can take place, for example 
the activity-dependent downregulation mediated by the transcription factor CREB. The 
binding site of CREB is not known, but USFs have been reported to function together with 
CREB and perhaps could be involved in the transcriptional repression of KCC2b mediated 
by CREB. 
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4.2 CELLULAR EXPRESSION PATTERN  
 
In study II we compared the expression pattern of KCC2a and KCC2b in different regions 
of postnatal mouse CNS by immunohistochemistry. Several different developmental time 
points were analyzed: E18, P3, P7, P12, and adult. In addition, some immunostainings from 
hippocampal formation in adult mouse was performed in study III. Rabbit anti KCC2pan 
and KCC2 isoform specific antibodies (rabbit anti-KCC2a, chicken anti-KCC2b and rabbit 
anti-KCC2b) were used in these studies. Double-stainings with the isoform specific 
antibodies raised in different species (rabbit vs. chicken) were performed in order to detect 
KCC2a and KCC2b in the same section. 
 
In study II, the nonspecific staining produced by the KCC2a antiserum in PFA-fixed brain 
sections (Uvarov et al, 2009) was reduced significantly when KCC2a antiserum was 
preabsorbed against brain sections from PFA-fixed KCC2a-KO mice. We tested the 
specificity of the KCC2a antiserum by staining sections of adult wild-type and KCC2a-KO 
mice perfusion-fixed with 4% PFA (Study II, Fig 1). In study II and III, 
immunohistochemical staining using the KCC2a antiserum with PFA-fixed adult sections 
were performed by using preabsorbed antibodies. However, methanol-acetone postfixation 
(Uvarov et al, 2009) was used in KCC2a immunostainings for the earlier time points: E18, P3 
and P12.  
 
New polyclonal antibodies against the KCC2b isoform were generated in chicken, and 
specificity of the antibodies was tested by western blot (Study II, Fig 2). In addition, a 
previously characterized KCC2b-specific antiserum (Uvarov et al, 2009, Hubner et al, 2001) 
was used to stain some mouse brain sections, and produced an identical labeling as the new 
chicken KCC2b antibodies. 
 
Our results showed that in general KCC2b expression increased postnatally especially in 
cortical regions, and expression was rather uniform in adult mouse brain, as has been 
reported previously. KCC2a immunoreactivity did not increase in cortical regions during 
development. Expression of KCC2a was found in several noncortical areas in mature mouse 
brain including the basal forebrain, hypothalamus, brainstem, and spinal cord. A summary of 
the postnatal KCC2a expression pattern is presented in Fig. 7. 
 
 
4.2.1 Telencephalon 
 
Previously it has been shown in in situ hybridization experiments, that KCC2 mRNA (both 
isoforms) can be seen in rodents in some regions of telencephalon before birth: such as the 
olfactory bulb, basal ganglia, amygdala and piriform cortex (Li et al, 2002, Wang et al, 2002, 
Stein et al, 2004). During postnatal development, expression gradually spreads into the 
neocortex and hippocampus, and adult levels are reached at P15 in mice (Wang et al, 2002, 
Stein et al, 2004, Rivera et al, 1999). 
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In immunohistochemistry, the overall pattern of KCC2a and KCC2b immunoreactivity in 
E18 mice was very similar (Uvarov et al, 2009): both isoforms were detected in the basal 
forebrain, while immunorectivity in cortical regions was undetectable. 
 
In study II, KCC2b immunoreactivity was widely seen in adult mouse neocortex and 
hipppocampus, while KCC2a immunoreactivity was very low in these regions in adult mouse 
(Study II; Figs 3 and 4). KCC2a immunoreactivity was mainly restricted to parts of the basal 
forebrain. However, while the distribution of KCC2b signal was strong in most areas of the 
basal forebrain in adult mouse, the KCC2a isoform was strongly expressed mainly in the 
globus pallidum and parts of the ventral pallidum but expressed was not seen in the caudate 
putamen. KCC2a signal was also low or absent the olfactory cortex (piriform area, olfactory 
tubercle).  
 
Although only very weak KCC2a labeling is seen in adult mouse cortex and hippocampus in 
general (Study II, Fig 3), we noted that clear KCC2a immunoreactivity is present in the 
subiculum of the hippocampal formation (Study III, Fig 5). Otherwise, the KCC2a signal in 
the hippocampus proper was very low or absent.  
 
 
4.2.2 Diencephalon 
 
In in situ hybridization experiments, KCC2 mRNA (both isoforms) have been detected in the 
hypothalamus and thalamus already at E12 when the diencephalon begins to form (Li et al, 
2002, Wang et al, 2002, Stein et al, 2004, Mikawa et al, 2002). In thalamus, KCC2 mRNA is 
first present in the dorsolateral nuclei where neuronal differentiation originates, while the 
dorsomedial parts do not express KCC2 until E18.5 (Li et al, 2002, Wang et al, 2002). It has 
also been noted, that KCC2 mRNA expression is downregulated after birth in the ventral 
posterior thalamic nucleus (Wang et al, 2002). 
 
In immunohistochemistry using the KCC2pan antibody in adult rat, immunostaining has 
been observed in all thalamic nuclei except the majority of the reticular nucleus (Bartho et al, 
2004). Also, various relay nuclei expressed different levels of KCC2: Immunoreactivity was 
the strongest in primary sensory relay nuclei (first order nuclei), in particular, the 
somatosensory ventral posterolateral and ventral posteromedial nuclei. In diencepalon, 
prominent KCC2pan immunoreactivity was also observed in zona incerta, ventral lateral 
geniculate nucleus, and anterior pretectal nucleus.  
 
In our study, both isoforms showed a rather similar pattern of strong labeling in mouse 
hypothalamus at E18.5, P3 and adult time points (Study II; Fig 5). At E18.5, the signal in 
hypothalamus was clearly stronger than in thalamus. At P3, KCC2a signal was the strongest 
in the region of hypothalamus, whereas KCC2b signal was clearly seen in the hypothalamus 
and thalamus and some signal was also detectable in cortical regions. In adult hypothalamus, 
KCC2a and KCC2b immunoreactivities were intense and seen evenly throughout 
hypothalamus.  
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In thalamus both isoforms showed a rather similar pattern of moderate or low labeling at 
E18.5 (Study III; Fig 5). All parts of the P3 thalamus were clearly positive for KCC2b, 
whereas KCC2a labeling was low or absent in most parts of the thalamus proper. In adult 
mouse, KCC2b was widely expressed in most parts of the thalamus. Most parts of the 
thalamus in adult mouse lacked KCC2a signal, immunoreactivity was seen only in the 
dorsomedial part and midline thalamic nuclei and in the ventral lateral geniculate nucleus. 
 
It has previously been reported that KCC2 mRNA expression in the habenular complex is 
very weak (Kanaka et al, 2001): The lateral habenular nucleus contained weakly labeled 
neurons, but no KCC2 mRNA signals were detected in the medial habenular nucleus. In 
another study, the inferior part of the medial habenula was demonstrated to lack KCC2 
protein expression (Kim and Chung, 2007). In our study, the large inferior part of the medial 
habenula also lacked KCC2 expression, but both isoforms were clearly detected in the 
superior part of the medial habenula (Study III, Fig 5).  Labeling for both KCC2a and KCC2b 
was concentrated in the large dendritic glomeruli. Both KCC2 isoforms were clearly 
expressed in the lateral habenula. 
 
 
 
4.2.3 Brainstem  
 
In in situ hybridization experiments, KCC2 transcripts (both isoforms) have been first 
detected in the immature brainstem by E10.5 in mice (Stein et al, 2004). In adult rat brainstem, 
strong KCC2 mRNA expression was observed in most parts of midbrain, pons and medulla 
(Kanaka et al, 2001). KCC2 mRNA was however not detected in the mesencephalic trigeminal 
nucleus (Kanaka et al, 2001). 
 
In our study, both KCC2 isoforms were widely and abundantly present in the large part of 
the brainstem (midbrain, pons and medulla) in P3, P12 and mature mouse (Study III; Fig 3 
and 6). However, KCC2a appeared to be selectively absent in the main auditory pathway 
neurons: In the midbrain, KCC2a immunoreactivity was relatively abundant in the superior 
colliculus but low or absent in the inferior colliculus. In the medulla, KCC2a 
immunoreactivity was absent in a central part of the ventral cochlear nucleus and the superior 
olivary complex (SOC). The lack of KCC2a immunoreactivity in SOC was observed already 
in P3 mice.  
 
The SOC consists of several nuclei, the main ones are the medial nucleus of the trapezoid 
body (MNTB), the medial superior olive (MSO), the lateral superior olive (LSO), and the 
superior paraolivary nucleus (SPN). All these nuclei appeared to lack KCC2a 
immunoreactivity, while KCC2b was clearly expressed in developing and adult mouse SOC 
nuclei (Study II, Fig 6). 
 
Previously it has been reported that KCC2pan immunoreactivity in the SOC nuclei is present 
already at P0 without a substantial increase during maturation (Lohrke et al, 2005). It was also 
observed, that KCC2 protein expression precedes the functional maturation of the 
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transporter in neurons of all SOC nuclei. The development from depolarizing to 
hyperpolarizing glycine action in SOC nuclei is completed by the onset of hearing (around 
P12), but plasma membrane-associated KCC2 immunoreactivity was found already at times 
when glycine was still depolarizing (Lohrke et al, 2005). This implies that the mere presence 
of KCC2 protein is not sufficient for hyperpolarizing glycine action in the various SOC 
nuclei.  
 
The functional activation of KCC2 has been studied particularly in the LSO, where the shift 
from depolarizing to hyperpolarizing glycine responses occurred at P4–5 (Lohrke et al, 2005). 
KCC2b immunoreactivity was abundant present in the plasma membrane, or in close 
proximity to it, in LSO neurons already at P0, when Cl− extrusion is not yet effective and 
glycine is depolarizing. This implied the presence of transport-inactive KCC2 protein during 
early development and that KCC2 transport activity in developing LSO neurons is not 
regulated via an intracellular retention mechanism (Blaesse et al, 2006). 
 
In LSO neurons from KCC2b-deficient mice, the intracellular Cl- concentration was affected 
in P12 neurons but not in immature P3 neurons, when compared to wild-type neurons. As 
the KCC2a isoform, according to our study, is not expressed in LSO neurons, the KCC2b 
isoform is thus responsible for the developmental increase in neuronal Cl– extrusion in P12 
LSO neurons as seen in these mice. In P3 LSO neurons KCC2b is thus expressed at a high 
level in a functionally inactive form, and the neurons generate depolarizing GABAA and 
glycine responses (Balakrishnan et al, 2003).  
 
The reason for (and consequences of) the lack of KCC2a in auditory brainstem neurons is 
not known. However, efficient inhibition is very important in auditory neurons and 
particularly in SOC in the process of sound localization. The MNTB nucleus contains 
principal glycinergic neurons that provide a strong inhibitory input onto the other SOC nuclei 
(MSO, LSO, and SPN). The main task of this inhibition by MNTB is to convert the excitatory 
input from the contralateral ear into a well-timed inhibitory input onto neurons of other SOC 
nuclei (Johnston et al, 2010, Nothwang, 2016).  
 
In the SPN, a synaptic target of the MNTB, plasticity of inhibition has been observed to take 
place via modulation of the KCC2 level (Yassin et al, 2014). The SPN neurons were able to 
modify the Cl− equilibrium potential and inhibitory strength of glycine via modulation of the 
KCC2 expression. Nitric oxide was shown to act postsynaptically through a cGMP 
dependent pathway to suppress KCC2 protein expression in SPN neurons and cause a 
depolarizing shift in reversal potential (Yassin et al, 2014). 
 
 
4.2.4 Cerebellum 
 
In mouse cerebellum, Purkinje cells already express KCC2 at E15.5 when they start to 
differentiate. At P3, KCC2 mRNA can also be detected in granular cells in mice, and 
expression increases with maturation (Stein et al, 2004). Cerebellar neurons continue to 
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exhibit marked up-regulation of KCC2 mRNA during postnatal development, and the adult 
pattern is reached at P21 in mouse and rat (Li et al, 2002, Mikawa et al, 2002).  
 
In previous reports, KCC2pan immunoreactivity was observed in mouse Purkinje cells at 
E17 and the signal increased with maturation and at P10 dendrites and cell bodies of Purkinje 
cells were clearly labeled (Takayama and Inoue, 2006). In Purkinje cells, KCC2 shifts from a 
diffuse cytoplasmic pattern to a predominant cell surface distribution between P7 to P15. 
Simultaneously KCC2 is preferentially recruited to climbing fiber synapses, augmenting the 
inhibitory GABAergic actions by incoming basket cell axons (Kawakita et al, 2013). In the 
internal granule cell layer at P5, KCC2pan immunoreactivity was observed after formation 
of first excitatory synapses with mossy fiber terminals, and at P10 KCC2pan positive synaptic 
glomeruli were clearly discernible (Takayama and Inoue, 2006). At P0 and P3, KCC2pan 
immunoreactivity was observed in the developing molecular layer and at P10 and in adult, 
dendrites and cell bodies of stellate and basket cells were clearly labeled (Takayama and Inoue, 
2006).  
 
KCC2 expression is rather uniform in the mature cerebellum. The granule cell layer of the 
adult mouse cerebellum has been shown to exhibit the most intense KCC2pan staining, and 
particularly intense immunostaining was observed in glomeruli within the granule cell layer 
(Williams et al, 1999). KCC2b immunoreactivity was noted to be stronger in ventrocaudal 
than in dorsal parts of the cerebellar cortex (Blaesse et al, 2006). 
 
We observed both KCC2a and KCC2b immunoreactivity in Purkinje cells at P3 and P7, but 
at P12 and adult, only KCC2b immunoreactivity was seen in Purkinje cells (Study II; Fig 6). 
It seems that KCC2a was expressed only transiently in the Purkinje cells. KCC2b 
immunoreactivity was seen both in the Purkinje cell somata and in dendrites at all 
developmental time points analyzed (E18, P3, P7, P12, and adult) and was associated with 
the somatic and dendritic plasma membrane in adult. In the granule cell layer, in granule cells 
and their dendritic glomeruli, KCC2b was clearly seen at P12 and was further increased with 
maturation. KCC2a signal was not detectable in the cerebellar granule cells at any age studied 
(P3, P12, adult). In adult mouse cerebellum, KCC2b immunoreactivity was rather uniform, 
but stronger in ventrocaudal parts, as reported previously (Blaesse et al, 2006).  
 
Although KCC2a immunoreactivity was not observed in the cerebellar cortex (except in the 
Purkinje cells at P3 and P7), KCC2a was clearly expressed in deep cerebellar nuclei 
(interposed nucleus, fastigal nucleus and dentate nucleus) of P12 and adult mice. Also, 
KCC2b was strongly expressed in cerebellar nuclei in P12 and adult mice. 
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Fig.7 Expression pattern of KCC2a protein in postnatal mouse brain  
The KCC2a expression pattern is represented in schematic drawings of mouse brain 
sections at three postnatal time points. Expression is indicated by gray colored areas as 
observed in the immunostainings: Lighter gray color corresponds to a low signal intensity 
and darker gray color to a high signal intensity.  
A) At birth, KCC2a is detected in hindbrain, midbrain and hypothalamus. Labeling is 
moderate/low in thalamus, basal forebrain and, olfactory bulb.  KCC2a is undetectable in 
cortical regions. On the whole, the pattern of KCC2a labeling is identical to the pattern of 
KCC2b expression at this time point. 
B) At P3, KCC2a is also detected in Purkinje cells of the cerebellum, similar to KCC2b. In 
the thalamus, KCC2a signal has decreased, in contrast to KCC2b that is already strongly 
expressed in thalamus at P3. KCC2a is not detected in cortical regions, whereas weak 
KCC2b labeling is already detectable in cortical regions in the P3 mouse. 
C) In the adult mouse, KCC2a labeling is very low in cortical regions (particularly in the 
neocortex) where KCC2b is now widely expressed. KCC2a is, however, detected in 
subiculum, although signal in the hippocampus proper is very low or absent. KCC2a is 
also low/absent in layers of the olfactory cortex including the piriform area and the 
olfactory tubercle. In the adult striatum, KCC2a is detected in the globus pallidum and 
parts of the ventral pallidum, but not in the caudate putamen. KCC2a signal is absent in 
most parts of the adult thalamus (thus KCC2a seems to disappear from thalamus by 
adulthood). In cerebellum KCC2a was detected in deep cerebellar nuclei, but the 
cerebellar cortex, including Purkinje cells, lacked KCC2a (thus KCC2a is apparently 
expressed in Purkinje cells only transiently, as signal is detected at P3 and P7 but not in 
P12 and adult). KCC2a labeling is abundant in brainstem, but some areas such as the 
superior olivary complex are negative. 
D) A frontal section through adult diencephalon (level indicated in C). KCC2a signal is 
strong in hypothalamus but absent in most parts of thalamus except for dorsomedial and 
midline thalamic nuclei, as well as the ventral lateral geniculate nucleus of thalamus. 
KCC2a is detected in the lateral habenula and in the superior part of the medial habenula 
in the dendritic glomeruli. 
E) A frontal section through adult pons (level indicated in C). KCC2a is widely present in 
adult brainstem, but signal is weak/absent in auditory system neurons, in particular in a 
central part of the ventral cochlear nucleus and in nuclei of the lateral superior olivary 
complex. KCC2a signal is also very low/absent in the inferior colliculus. (KCC2a labeling 
is also absent in the auditory medial geniculate nucleus of thalamus.)  
Abbreviations: ACB, nucleus accumbens; AQ, aqueduct; BF, basal forebrain; CBX, 
cerebellar cortex; CP, caudate-putamen; CTX, cerebral cortex; DCN, deep cerebellar 
nucleus; DT, dorsal thalamus; GP, globus pallidus; HB, hindbrain; HC, hippocampus; HY 
hypothalamus; Hyp, hypothalamus; IC, inferior colliculus; LGd, dorsal lateral geniculate 
nucleus; LGv, ventral lateral geniculate nucleus; LHb, lateral habenula; LSO, lateral 
superior olive; LV, lateral ventricle; MB, midbrain; MHb, medial habenula; MNTB, medial 
nucleus of the trapezoid body; MSO, medial superior olive; MY, medulla; OB, olfactory 
bulb; OT, olfactory tubercle; P, pons; PCs, Purkinje cells; PIR, piriform area; PO, posterior 
complex of the thalamus; Py, pyramidal tract; Rt, reticular nucleus of the thalamus; SC, 
superior colliculus; SI, substantia innominate; SNc, substantia nigra, compact part; SNr, 
substantia nigra, reticular part; SOC, superior olivary complex; SPN, superior periolivary 
nucleus; SUB, subiculum; TH, thalamus; 3V, third ventricle; VCO, ventral cochlear 
nucleus; VP, ventral posterior complex of the thalamus. 
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4.2.5 Spinal cord 
 
KCC2 transcripts are detected in mice in the ventral horn of the spinal cord by E10.5 in in 
situ hybridization (Stein et al, 2004), and the expression spreads in a caudal-rostral fashion. In 
developing mouse motoneurons in the ventral horn of the spinal cord, KCC2 transcripts 
have been detected at E12.5 and in sensory neurons at later stages (Hubner et al, 2001). At 
E18.5, KCC2 transcripts were detectable throughout the spinal cord along the complete 
neuraxis (Hubner et al, 2001).  
 
KCC2b immunostaining in the spinal cord developed along latero–medial and ventro–dorsal 
gradients (Stil et al, 2009). At P0, KCC2b immunolabeling was observed in the ventral horn 
and expression of KCC2b markedly increased in the whole spinal cord between P0 and P5. 
KCC2b immunoreactivity in the medial grey matter, where the central pattern generator -
interneurons are located, and the most superficial layers of the dorsal horn was weak at P0 
(Stil et al, 2009). 
 
At E18.5 KCC2b immunostaining in the mouse ventral horn of spinal cord has been detected 
mainly in dendrites and in the adult, KCC2b was clearly localized at the plasma membrane 
of dendrites, enriched at the periphery of the postsynaptic specialization of inhibitory 
synapses (Hubner et al, 2001). KCC2b immunoreactivity was observed at the plasma 
membrane of somas and dendrites already at birth in motoneurons of mouse spinal cord. 
Dendrites throughout the neuropil and the white matter strongly expressed KCC2b at P5. 
Labeled neurites (dendrites) stretched out of the gray matter in into the lateral and ventral 
funiculi at this developmental time-point (Jean-Xavier et al, 2006).  
 
We detected both KCC2 isoforms in the ventral part of mouse spinal cord already at E12 
and in newborn, labeling for KCC2 isoforms showed a relatively similar even distribution in 
both dorsal and ventral parts (Study III, data not shown). This is in line with previous data 
demonstrating similar expression level of both isoforms in neonatal spinal cord (Uvarov et 
al, 2007, Uvarov et al, 2009). Abundant expression of both KCC2 isoforms in the large part 
of the developing and mature spinal cord was observed at P3 (Study III, Fig 7). Similarly, in 
adult mouse spinal cord, the KCC2a and KCC2b labeling showed a relatively similar and 
even distribution. We also observed KCC2a and KCC2b immunoreactivity in putative 
dendrites extending into the white matter in adult spinal cord.  
 
 
4.3 SUBCELLULAR LOCALIZATION 
 
4.3.1 Different surface expression 
Electron microscopic studies have demonstrated that most KCC2pan and KCC2b 
immunoreactivity is found associated with the plasma membrane both in somatic and 
dendritic compartments in mature neurons (Gulyas et al, 2001, Baldi et al, 2010, Gulacsi et al, 
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2003, Bartho et al, 2004, Szabadics et al, 2006, Takayama and Inoue, 2006, Belenky et al, 2008, 
Hubner et al, 2001, Boulenguez et al, 2010, Blaesse et al, 2006). 
 
The subcellular localization of KCC2a and KCC2b was studied in several areas of adult 
mouse CNS using double-staining with isoform-specific antibodies and confocal microscopy 
analysis (Study II; Fig 8). In PFA-fixed brain sections, KCC2b immunoreactivity was seen at 
the plasma membrane of the somas and proximal dendrites of virtually all CNS neurons, 
while KCC2a was not clearly detected at the surface. In study II we focused on two areas 
with high KCC2a expression in adult mouse: deep cerebellar nucleus and pons. In neurons 
of the deep cerebellar nucleus, KCC2b was clearly concentrated at the plasma membrane in 
the soma region, while KCC2a signal was not detectable at the surface of neuronal somas or 
in the region of proximal dendrites. Similar results were obtained in the region of the pons, 
where only the KCC2b isoform is seen at the surface of the soma and proximal dendrites.  
 
KCC2a signal also co-localized with MAP2, as shown in a confocal microscopy image in a 
section through the pons double-stained with anti-KCC2a and anti-MAP2 (Study II; Fig 8). 
KCC2a thus is preferentially located in neuronal dendrites. 
 
In study III we further analyzed KCC2a and KCC2b surface expression in PFA-fixed adult 
mouse brain, but focused on brain areas with medium level of KCC2a expression: subiculum 
and hypothalamus (Study III; Fig 5). Similar to study II we used double-staining with isoform-
specific antibodies and confocal microscopy analysis. In subiculum, KCC2a labeling was 
clearly seen at the neuronal soma surface of neurons, similar to KCC2b labeling. In some 
hypothalamic neurons, KCC2a was also seen at the soma surface although not as clearly as 
the KCC2b signal. In both subiculum and hypothalamus, KCC2b labeling was clearly 
detected at soma surface and the area of proximal dendrites. For comparison, KCC2b but 
not KCC2a labeling was detected at the plasma membrane of neuronal somas in the medulla 
oblongata, as observed in pons and deep cerebellar nuclei in study II.  
 
In study III we also showed that KCC2b immunoreactivity is localized at the plasma 
membrane of neurons in sections from PFA-fixed KCC2a-KO mouse brain as seen in wild-
type. Confocal microscopic images of anti-KCC2b labeled neurons from the hypothalamus, 
subiculum, CA1 and medulla were presented (Study III; Suppl. Fig 1).  
 
Moreover, we found that KCC2pan immunoreactivity can be seen at the surface in some 
neurons in PFA-fixed brain sections from PFA-fixed KCC2b-KO mouse (Woo et al., 2002) 
in the pons region. However, as in wild type, plasma membrane KCC2a immunoreactivity 
was not detected by the KCC2a antibody in KCC2b-deficient neurons (Study III; Suppl. Fig 
5). Since the KCC2pan antibody recognizes the common C-terminus of KCC2 (Williams et 
al, 1999), and KCC2a isoform is the only expressed KCC2 isoform in these mice (Uvarov et 
al, 2007) the KCC2 pan immunoreactivity in these mice represents the KCC2a distribution. 
Thus, it seems that KCC2a can be detected at the surface of neurons in the pons when using 
the KCC2pan antibody, but not with the N-terminal KCC2a antibody.  
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The surface expression of endogenous KCC2 isoforms was also examined in two-week-old 
dissociated rat cortical cultures fixed with methanol (Study III; Fig 4). Immunostaining with 
the isoform specific antibodies revealed that KCC2b immunoreactivity was observed in all 
neurons at that time point, and in about half of them KCC2b signal was observed at the 
plasma membrane of the soma and proximal dendrites, while the cytoplasm was only weakly 
labeled. In contrast, KCC2a-immunoreactivity was detected exclusively in the intracellular 
compartments and it was not observed at the surface of somas or proximal dendrites in any 
of the neurons. Surprisingly, biotinylation assay in the same kind of neuronal cultures (two-
week-old dissociated rat cortical cultures) revealed that the relative surface representation of 
KCC2a and KCC2b isoforms (monomers) was about 40 % of the total expression level for 
each of the isoforms (Study III; Fig4). The discrepancy between the immunostaining and 
biotinylation data also suggests that the N-terminal epitope of KCC2a may be masked at the 
plasma membrane. 
 
The differential surface expression of endogenous KCC2 isoforms was also observed in 
cultured mouse hippocampal neurons fixed with methanol (Study III; Suppl. Fig 4). The 
hippocampal neurons were stained with KCC2a or KCC2pan antibodies at two different 
time-points: DIV5 and DIV19. KCC2a and KCC2pan immunoreactivity was present in cell 
bodies and dendritic shafts already at DIV5 but immunoreactivity was predominantly 
intracellular with both antibodies. In DIV19 neurons the KCC2a labeling was largely similar 
as in DIV5, only a weak KCC2a signal could be seen at the soma surface in some neurons. 
KCC2pan-immunoreactivity was clearly and predominantly detected at the neuronal surface 
in DIV19 neurons. Thus, in the more mature hippocampal neurons (DIV19) and cortical 
neurons (DIV14), a similar difference in localization of endogenous KCC2 isoforms is 
observed.  
 
To conclude, our results indicate that KCC2a immunoreactivity (when using the N-terminal 
isoform specific antibody) is not detected at or near the plasma membrane of somas and 
proximal dendrites of neurons in most brain regions. The immunostaining data from cultured 
neurons is also in agreement with results from immunostainings of brain sections. The 
resolution of confocal microscopy is not enough in order to determine actual vs. near 
membrane expression, but the results clearly show the different distribution of KCC2a 
immunoreactivity compared to KCC2b when using isoform specific antibodies: KCC2a 
immunoreactivity in soma and proximal dendrites is concentrated in intracellular 
compartments but it is not seen at or near the plasma membrane. With confocal microscopy 
it is also not possible to analyze the intracellular vs surface expression in the thin distal 
dendrites. 
 
It is possible that the intracellular retention or targeting to the cell surface might be different 
for the KCC2 isoforms as the unique N-terminal part of KCC2a may contain targeting signals 
different from those of KCC2b. Indeed, truncation of the N terminus of KCC2b has been 
shown to affect the surface expression of the protein (Friedel et al, 2017). However, when 
using the C-terminal KCC2pan antibody, KCC2a can be detected at the surface of neurons 
in the pons in KCC2b-deficient mice, rather suggesting that the N-terminal epitope of 
KCC2a at the surface is masked. Results from biotinylation assay also support the hypothesis 
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of the masked N-terminal epitope, as both KCC2 isoforms are similarly present at the plasma 
membrane of two-week-old cultured cortical neurons in contrast to what was observed in 
immunocytochemistry.  
 
The N-terminal epitope of KCC2a and/or KCC2b may be differentially masked, for example 
by a protein that binds to the N-terminal epitope of KCC2a at the plasma membrane. A 
possible candidate for the KCC2a epitope masking is SPAK since the binding motif 
RFx(V/I) for SPAK is located in the unique N-terminal part of the KCC2a, near the anti-
KCC2a epitope (Uvarov et al, 2007). The heterogeneous expression pattern of SPAK protein 
(Ushiro et al, 1998, Johnston et al, 2000, Piechotta et al, 2003) in the mouse brain could explain 
why KCC2a immunoreactivity is detected nearby neuronal surface in some but not other 
brain regions. For example, SPAK mRNA expression pattern in adult mouse brain is low in 
subiculum and hypothalamus, while much stronger in deep cerebellar nucleus or medulla 
(Allen Brain Atlas) (Study III; Suppl. Fig. 6). 
 
 
 
 
4.3.2 Different subcellular targeting 
 
In immunostaining of adult mouse brain sections, KCC2a is preferentially located in neuronal 
dendrites (co-localized with MAP2) (Study II; Fig. 8), and KCC2a and KCC2b 
immunoreactivity are overlapping in many parts of dendrites. Previously a similar cellular 
distribution of KCC2 isoforms was observed in immunohistochemistry in E18 mouse brain 
where most neurons in non-cortical brain structures were positive for both KCC2a and 
KCC2b and most positive neurons were observed to co-express KCC2a and KCC2b (Uvarov 
et al, 2009). As KCC2a and KCC2b have also been shown to form heterodimers in vivo 
(Uvarov et al, 2009), the co-localization could represent such subdomains were heterodimers 
are present. 
  
However, in the dendrites, KCC2a localization seems to be at least partially different from 
that of KCC2b as the signals are not completely overlapping in KCC2a-KCC2b double-
stainings in deep cerebellar nucleus and pons (Study II; Fig. 8), as well as in subiculum, 
hypothalamus and medulla (Study III; Fig 5). It appears that KCC2a signal could be more 
localized to distal dendrites as compared to KCC2b signal that is clearly seen in soma and 
proximal dendrites. Also in a section of adult mouse lumbar spinal cord, double-labeled with 
anti-KCC2a and anti-KCC2b, the distribution of KCC2 isoforms seems to be somewhat 
different in the putative dendritic branches projecting into the white matter (Study II; Fig. 7).  
 
In electron microscopic studies, KCC2pan immunoreactivity is usually evenly distributed 
along the somato-dendritic axis of neurons and is seen along the membrane of dendrites with 
different diameters (Takayama and Inoue, 2006, Bartho et al, 2004, Baldi et al, 2010). 
However, in CA1 pyramidal neurons the dendritic distribution of KCC2 was somewhat 
heterogenous (Baldi et al, 2010). In OFF bipolar cells and starburst cells of the retina, KCC2 
is confined in distal dendrites (Vardi et al, 2000, Gavrikov et al, 2006). KCC2b isoform 
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immunoreactivity is also concentrated at the plasma membrane of somas and dendrites in 
spinal motoneurons (Boulenguez et al, 2010, Hubner et al, 2001, Stil et al, 2011) and in 
brainstem auditory neurons (Blaesse et al, 2006) and enriched near inhibitory and excitatory 
synapses (Blaesse et al, 2006, Hubner et al, 2001). 
 
The partly different dendric localization of KCC2 isoforms could reflect different subcellular 
targeting of the isoforms to different parts of the neuron. For example, work on NKCC1 in 
epithelial cells suggests that alternative splicing can play a major role in differential subcellular 
targeting (Carmosino et al, 2008). However, mechanisms that underlie the differential 
subcellular targeting of distinct CCCs to different somato-dendritic compartments are not 
known. Several mechanisms could be involved including oligomerization, and protein-
protein interactions for example with scaffolding molecules. The mechanisms of KCC2 
clustering to various subdomains may also involve cholesterol-enriched lipid rafts (Watanabe 
et al, 2009).  
 
However, as discussed in the previous section (4.3.1), the lack of KCC2a/KCC2b co-
localization could also result from masking of the KCC2a epitope in some dendritic locations, 
for example in proximal dendrites and soma. Alternatively, the N-terminal epitope of KCC2b 
could also be masked in some subcellular locations. A hypothetical model of KCC2 isoforms 
and their targeting in a mature neuron is shown in Fig. 8, also taking into account the possible 
effect of masking of the KCC2a N-terminus. 
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Fig. 8 Hypothetical scheme on the targeting of KCC2a and KCC2b in a mature 
neuron. 
A model of a mature neuron, expressing KCC2a and KCC2b isoforms (KCC2b being the 
more abundant isoform). KCC2a and KCC2b are both equally present in the plasma 
membrane according to our biotinylation assay, while a fraction of KCC2 molecules are 
in intracellular compartments, presumably in vesicles (V) near the plasma membrane. 
KCC2 molecules are recycled between the plasma membrane and intracellular 
compartments (1). The unique N-terminus of the KCC2a isoform might require additional 
modifications (protein-protein interactions, phosphorylation) in order to be transported to 
the plasma membrane. In this model, a protein binds the KCC2a N-terminus before it is 
transported to the membrane (2) and this masks the KCC2a N-terminus at the plasma 
membrane. KCC2 has been suggested to function as oligomers in the plasma membrane 
(presumably as dimers), but details about how or where they form is not known. In a 
mature neuron, KCC2b-KCC2b homodimers/oligomers (3) would probably be the 
predominant form, while a fraction would represent KCC2a-KCC2b heterodimers (4), and 
even smaller fraction could be KCC2a-KCC2a homodimers (5). The regulation of these 
different oligomers might differ due to different interacting partners or phosphorylation etc. 
Immunostainings show that KCC2a and KCC2b labeling are often co-localized and 
KCC2a and KCC2b are thus probably often localized to the same microdomains (for 
example membrane rafts). However, we also observed non-overlapping KCC2a and 
KCC2b immunoreactivity, suggesting that the isoforms might occasionally localize in 
different microdomains. In this model, KCC2a is shown to aggregate in some vesicles that 
do not contain KCC2b in the distal dendrite (6). N, nucleus; ER, endoplasmic reticulum; 
G, Golgi apparatus; V, vesicle 
 
 
 
4.4 FUNCTION AND REGULATION 
 
4.4.1 KCC2a functionality 
 
Previous studies suggested involvement of the N-terminus of the K-Cl cotransporters into 
regulation of the transport activity (Casula et al, 2001, Shen et al, 2003, Li et al, 2007, Horn et 
al, 2010, Fiumelli et al, 2013). It has also been shown previously that both KCC2 isoforms 
demonstrate similar levels of chloride transport activity in rubidium-flux assays when 
overexpressed in HEK293 cells (Uvarov et al, 2007), showing that KCC2a protein can be 
transported to the cell surface in hEK293 cells and function as a chloride transporter. 
However, in dissociated cortical neurons derived from KCC2b-knockout embryos, where 
KCC2a is the only expressed KCC2 isoform, no significant decrease in intracellular chloride 
concentration [Cl−]i after 3 weeks in culture was revealed, in contrast to the significant 
decrease of [Cl−]i in wild-type neurons (Zhu et al, 2005).  
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In study III we set out to study the functionality of KCC2a in cultured neurons as the model 
system. In previous reports (Ludwig et al, 2003, Fiumelli et al, 2005, Zhu et al, 2005, Khirug 
et al, 2005, Leonzino et al, 2016), the total KCC2 expression increased ~5-fold during the first 
week and ~3-fold during the second week in culture. Developmental upregulation of the 
KCC2 protein expression has been observed in dissociated mouse cortical cultures by ICC 
(Zhu et al, 2005) and in mouse hippocampal cultures by Western blot (Fiumelli et al, 2005),.  
 
We started by studying the expression of endogenous KCC2 isoforms in cortical cultures at 
the level of protein and mRNA at DIV2, DIV8 and DIV14 (Study III; Fig. 1). To assess the 
proportion of  the KCC2a isoform to the total KCC2 (KCC2a+KCC2b) protein expression 
in maturing cortical neurons, we used the previously developed method of  running of  
KCC2a protein standards on the same SDS-PAGE alongside with experimental protein 
lysates (Uvarov et al, 2009). Even though KCC2a levels also increased during the two weeks 
in culture, the upregulation was not so pronounced (~3.5-fold for the 1st week, and ~2-fold 
for the 2nd week) compared to the total KCC2 levels. Proportion of  KCC2a to total KCC2 
protein expression decreased gradually with maturation of  dissociated cortical cultures. The 
relative proportion of  KCC2a to the total KCC2 protein expression was ~40 % in DIV2, 
~30 % in DIV8, and ~20 % in DIV14 dissociated cortical cultures. Quantitative RT-PCR 
was used to measure KCC2a and KCC2 total mRNA levels in DIV2, DIV8 and DIV14 
dissociated cortical cultures, and the developmental profile of mRNA data was in a good 
agreement with the protein data.  
 
We also studied the efficacy of chloride extrusion mediated by overexpressed KCC2a in 
dissociated hippocampal cultures using electrophysiology (Study III; Fig. 2). One-week-old 
neuronal cultures derived from mouse embryos deficient for both KCC2 isoforms were 
transfected with KCC2a and analyzed two days after the transfection. Whole-cell patch-
clamp recordings from soma under a constant Cl- load via a somatic patch pipette were 
performed and the somatodendritic gradient of reversal potential EGABA was measured 
(Khirug et al, 2005). The imposed EGABA gradient was significantly larger in the KCC2a-
transfected neurons compared to neurons transfected with the empty vector. Thus, 
exogenous KCC2a promotes active chloride extrusion and increases EGABA gradient in 
cultured neurons.  
 
In addition, we studied the efficacy of chloride extrusion mediated by overexpressed KCC2a 
in dissociated rat cortical cultures using calcium imaging (Study III; Fig 3). Wild-type neuronal 
cultures were used in this experiment, but calcium transients were recorded at DIV6 when 
endogenous KCC2 expression is still low (Ludwig et al, 2003, Khirug et al, 2005, Uvarov et al, 
2006, Fiumelli et al, 2005) and GABAA responses are predominantly depolarizing 
(Chudotvorova et al, 2005, Khirug et al, 2005). The cultures were transfected with a plasmid 
expressing either one of the KCC2 isoforms or just an empty vector as a control. Calcium 
responses were recorded after application of GABAA receptor agonist muscimol to the 
neuronal cultures. Depolarizing GABAA responses can directly activate voltage-gated calcium 
channels, and thus result in increased intracellular calcium levels that can be recorded using 
Fura-2 AM calcium imaging protocol. We asked whether exogenous KCC2a overexpression 
in cultured neurons could also induce a shift in responses of GABAA receptors from 
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depolarizing to hyperpolarizing. Overexpression of either KCC2a or KCC2b isoform caused 
a dramatic decrease in the fraction of responding neurons (~15 %) compared to in neurons 
transfected with the empty vector (above 60%). There was no significant difference between 
KCC2a or KCC2b isoforms in this experiment, thus the KCC2a isoform is active in cultured 
neurons and can reduce the intracellular chloride concentration to the level sufficient for 
attenuating the depolarizing responses of the GABAA receptors. 
 
In conclusion, our results show that overexpressed KCC2a isoform can decrease the 
intracellular chloride concentration in cultured neurons. However, data from cultured 
neurons from KCC2b-deficient mice could indicate that the KCC2a isoform might not be 
functional in vivo (Zhu et al, 2005). In that study, the KCC2b isoform clearly mediates the 
developmental decrease in intracellular Cl- and is responsible for the developmental shift 
from depolarizing to hyperpolarizing GABAergic responses. On the other hand, our results 
also demonstrate that the KCC2a isoform constitutes only ~20 % (or less) of the total KCC2 
expression in the mature cortical cultures and this could explain why [Cl-]i remains unchanged 
in the cultured KCC2b-deficient cortical neurons.  
 
 
 
4.4.2 Regulation by SPAK 
 
The 40-amino-acid long N-terminus unique for KCC2a contains the binding motif for the 
SPAK kinase (Uvarov et al, 2007). Binding of SPAK to the KCC2 isoforms was studied in 
co-immunoprecipitation experiments in HEK293 cells (Study III; Fig. 6). In co-
immunoprecipitation with the KCC2pan antibody from HEK293 lysates, SPAK interaction 
with KCC2a is substantially stronger than that with KCC2b. The co-immunoprecipitation 
assay was also performed using anti-HA antibody to precipitate protein complexes from the 
same HEK293 lysates. Precipitation with the anti-HA antibody was not as effective as with 
the KCC2pan antibody, yet detectable HA-SPAK enrichment was observed.  
 
The functional 86Rb assay in HEK293 cells was used to study regulation of the KCC2a and 
KCC2b transport activities by SPAK (Study III; Fig 7). HEK293 cells are a widely used 
mammalian expression system for CCC transporters (Moore-Hoon and Turner, 2000, Simard 
et al, 2004, Wenz et al, 2009), and have been extensively used for studying SPAK-mediated 
regulation of CCCs. HEK293 cells express endogenously KCC1, KCC4, and NKCC1 
proteins (Xu et al, 1994, Simard et al, 2007), but neither KCC2a nor KCC2b (Payne et al, 1996, 
Williams et al, 1999, Uvarov et al, 2009). SPAK and OSR1 kinases, as well as their upstream 
kinase WNK1, are expressed endogenously in HEK293 cells (Vitari et al, 2006, Rinehart et al, 
2009). 
 
In our experiments, HEK293 cells were transiently transfected with constructs encoding 
either KCC2a or KCC2b isoforms. Rubidium assay was performed to measure the influx 
mode of the KCC2 transport activity (Payne, 1997, Uvarov et al, 2007). The 86Rb+ flux was 
measured with and without furosemide (2 mM), an inhibitor of KCC cotransporters, to 
determine the furosemide-sensitive component of the K-Cl transport activity. Bumetanide 
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(10 μM), a potent inhibitor of NKCC1 protein (Xu et al, 1994), was added into all flux 
solutions to exclude NKCC1 impact on 86Rb uptake. SPAK overexpression decreased the 
transport activity of KCC2a (by ~20 %) but not that of KCC2b.  Since our experiment was 
performed in isotonic solution and without adding WNK, the activity of overexpressed 
SPAK was probably relatively low and this may be the reason for the relatively mild decrease 
in the transport activity of KCC2a. Regarding KCC2b isoform, it has been shown previously 
that SPAK overexpression in oocytes inhibited KCC2b transport activity in hypotonic/low 
chloride conditions even though KCC2b isoform lacks SPAK-binding motifs (Gagnon et al, 
2006). However, KCC2b inhibition in isotonic conditions after SPAK overexpression in the 
absence of WNKs was not observed, similar to our experiment. 
 
To test whether KCC2a and KCC2b isoforms are regulated by endogenous SPAK/OSR1 in 
HEK293 cells, we overexpressed the dominant negative SPAK (DNSPAK) (Dowd and 
Forbush, 2003) (study III; Fig. 7). This DNSPAK contains a single amino acid substitution 
(K101R) within the catalytic domain that impairs its kinase activity. DNSPAK can bind 
proteins at the same sites as SPAK, but cannot phosphorylate them. DNSPAK 
overexpression strongly enhanced the furosemide-sensitive 86Rb uptake mediated by KCC2a 
(3.2-fold) and KCC2b (2.6-fold) relative to the cells transfected with KCC2a or KCC2b 
constructs only. Increase in the transport activity of KCC2b has been observed previously 
after overexpression of DNSPAK in Xenopus oocytes (Gagnon et al, 2006).  
 
The functional 86Rb assay was performed by substituting the K+ by 86Rb+ in the extracellular 
solution and the influx mode of the KCC2 transport activity was measured (Payne, 1997, 
Uvarov et al, 2007). When no SPAK is overexpressed endogenous SPAK/OSR1 in HEK293 
cells are presumably active and inhibit the function of both KCC2a and KCC2b via 
phosphorylation. Endogenous WNKs in HEK293 cells may also function to inhibit the 
activity of KCC2 in a SPAK-independent manner, for example by inhibition of protein 
phosphatases. Endogenous SPAK/OSR1 may also regulate the function of other 
endogenous KCCs (KCC1, KCC3, KCC4) that are present in HEK293 cells. When SPAK is 
overexpressed, a relatively mild decrease in the transport activity of KCC2a was detected but 
not in that of KCC2b. The overexpressed SPAK probably binds KCC2a and is thus able to 
increases the phosphorylation status of KCC2a. When DNSPAK is overexpressed, it 
presumably binds KCC2a at the SPAK-binding site and prevents binding and 
phosphorylation by endogenous SPAK/OSR1. Since DNSPAK overexpression strongly 
enhanced the furosemide-sensitive 86Rb uptake mediated by both KCC2a and KCC2b it 
implies that DNSPAK probably inhibits the activation (phosphorylation) mediated by 
endogenous SPAK/OSR1 in HEK293 cells, and KCCs are dephosphorylated. Again, the 
mechanism of DNSPAK is not clear regarding KCC2b, but DNSPAK could for example 
inhibit the repression of WNKs on protein phosphatases by binding endogenous WNKs. In 
Fig. 9 a hypothetical scheme on regulation of KCC2a and KCC2b by SPAK is shown. 
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Fig. 9. Hypothetical scheme on the regulation of KCC2a and KCC2b by SPAK.  
KCC2 on the plasma membrane probably exists as KCC2b-KCC2b homodimers, KCC2a-
KCC2a homodimers and KCC2a-KCC2b heterodimers. KCC2b homodimers would 
predominate in a mature neuron. Under normal physiological conditions (1), WNK is active 
and activates SPAK that binds to the SPAK binding site of KCC2a and thus is able to 
phosphorylate KCC2a in KCC2a-KCC2a homodimers and both KCC2a and KCC2b in 
KCC2a-KCC2b heterodimers. However, KCC2b molecules in KCC2b-KCC2b 
homodimers are also phosphorylated by the WNK-SPAK pathway, but since SPAK does 
not seem to bind KCC2b in HEK cells, the mechanism is not clear. Simultaneously, protein 
phosphatases are inactivated by WNK (2) and this helps to maintain the phosphorylation 
state of KCC2 molecules. WNKs may function to inhibit the activity of KCC2b in a SPAK-
independent manner via inhibition of protein phosphatases. When the KCC2 molecules 
are phosphorylated, as in normal physiological conditions, the ion-transport activity of 
KCC2 is not particularly high. When the intracellular Cl- concentration is increased (3), Cl- 
ions bind to WNK and inactivate it. WNK is no longer able to activate SPAK and 
simultaneously, the inhibition of protein phosphatases is lost. Protein phosphatases thus 
are able to dephosphorylate KCC2 molecules (4) and the ion transport activity is 
increased. 
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5. CONCLUSIONS AND OPEN QUESTIONS 
 
The KCC2 gene produces two isoforms, KCC2a and KCC2b, with different N-termini. Both 
isoforms are transcribed from different promoters, but the initial expression of the isoforms 
seems to be controlled by common mechanisms as both isoforms are largely neuron specific 
(Uvarov et al, 2007), and the pattern of KCC2a and KCC2b expression is similar in embryonic 
and neonatal mouse CNS (Uvarov et al, 2009) (Study II). The understanding of the 
mechanisms that control the initial neuron-specific expression of KCC2 isoforms still remain 
incomplete, but common enhancers or regulatory elements rather than individual promoter 
sequences might be important. For example, data on the involvement of NRSF in the 
neuron-specific expression of KCC2b are controversial (Karadsheh and Delpire, 2001, 
Uvarov et al, 2005, Yeo et al, 2009). Alterations of the chromatin state, for example DNA 
methylation, might also be an important component of regulation. 
  
During the first postnatal weeks in mouse, KCC2b expression is strongly increased in cortical 
regions. The KCC2b promoter contains several binding sites for activity-dependent 
transcription factors that probably participate in the developmental upregulation of the 
KCC2b isoform, such as Egr4 (Uvarov et al, 2006) and USFs identified in study I of this 
thesis. In addition to Egr4 and USFs, several additional transcription factors are likely to 
participate in the transcriptional regulation of the KCC2b isoform, but have not been studied 
so far. The upstream signaling pathways involved in activation of transcription by USFs also 
remain to be identified. 
 
Although KCC2 isoforms have an overlapping expression profile in the developing mouse 
CNS, KCC2a expression remains low in most cortical neurons in adult. The KCC2a 
promoter contains putative binding sites for general transcription factors that are not 
particularly enriched in neurons (Uvarov et al, 2007), and in line with this, KCC2a is not 
upregulated in neurons during postnatal development. In immunostainings performed in 
study II, KCC2a protein was detected in the basal forebrain, hypothalamus, and many areas 
of the brainstem and spinal cord, but not in most cortical regions in adult mouse brain. 
  
Various data also indicate that KCC2a may exhibit a broader tissue distribution in vertebrates, 
in contrast to KCC2b, which seems to be predominantly CNS neuron specific. In one study 
KCC2a was the only variant detected in human lens epithelial cells (Lauf et al, 2012). In 
chicken heart, KCC2a was the predominant splice variant and was robustly expressed in 
cardiomyocytes (Antrobus et al, 2012). KCC2a (and a splice variant of KCC2a isoform lacking 
exon 24) was also the predominant isoform identified in pancreatic β-cells in mouse and 
human (Kursan et al, 2017). Thus, some role of KCC2a outside the CNS, for example in 
insulin secretion in pancreas, is also possible. 
 
A downregulation of KCC2b at the mRNA and protein level is observed in various 
pathological conditions, and has been particularly studied in various forms of epilepsies. The 
mechanisms involved in the activity-dependent downregulation of KCC2b in pathological 
conditions have not yet been well characterized at the transcriptional level. When KCC2b is 
downregulated, NKCC1-mediated accumulation of intracellular chloride results in 
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depolarizing and even excitatory GABAergic events. GABA-mediated depolarizations might 
result in increased intracellular Ca2+ via voltage gated calcium channels, such as the L-type 
channels, or NMDARs. The increase in intracellular Ca2+ induces signaling events that may 
regulate the activity-dependent downregulation of KCC2b at the transcriptional level.  
 
Increased neuronal activity under pathophysiological conditions may also lead to a 
downregulation of KCC2 transport function mediated by posttranslational modifications, 
such as changes in phosphorylation/dephosphorylation. For example, pathological-like 
patterns of neuronal activity have been demonstrated to initiate a rapid (30-60 min) 
withdrawal of KCC2 from the plasma membrane that leads to a reduction of KCC2-mediated 
ion-transport (Rivera et al, 2004). Levels of glutamate may increase within the brain during a 
seizure and mediate a NMDAR-dependent Ca2+ influx that activates protein phosphatase 1 
and results in subsequent dephosphorylation of KCC2 S940 (Lee et al, 2011). 
Dephosphorylation was demonstrated to inhibit KCC2 activity and to decrease its membrane 
stability. Glutamate-mediated Ca2+ influx through activated NMDARs and S940 
dephosphorylation also favored calpain cleavage of KCC2 C-terminal domain leading to 
KCC2 internalization and degradation (Puskarjov et al, 2012). 
 
Mutation /polymorphism in the KCC2 gene has been identified in relationship to idiopathic 
epilepsies in humans (see Fig. 4). Mutations R952H and R1049C in KCC2 were found to be 
associated with idiopathic generalized epilepsy in humans, and both mutations decreased the 
level of KCC2 S940 phosphorylation and the plasmalemmal expression of KCC2 and acted 
in a dominant-negative manner (Kahle et al, 2014, Puskarjov et al, 2014). R952H substitution 
was also observed to cause a decreased dendritic spine density and altered spine morphology 
(Puskarjov et al, 2014). L311H, L426P and G551D mutations were identified as a cause of 
epilepsy of infancy with migrating focal seizures, and these mutations reduced the surface 
expression and glycosylation of KCC2 (Stodberg et al, 2015).  Mutations M415V, A191V and 
S323P impaired the transport function of KCC2 but produced no changes in the surface 
expression was detected (Saitsu et al, 2016). A deletion associated with epilepsy, E50–Q93 in 
the N terminus caused by skipping of exon 3 also resulted in significant loss of KCC2 
function (Saitsu et al, 2016). 
 
Seizure-induced downregulation is likely to primarily involve the KCC2b isoform, as this 
isoform is widely expressed in the adult brain and known to be important for inhibition. This 
is also supported by observations in transgenic animals, as KCC2b knockout mice die a few 
weeks postnatally due to spontaneous seizures (Woo et al, 2002). The characterization of 
KCC2a-isoform deficient mice is still ongoing, but the mice appear to have a normal life span 
and do not present spontaneous seizures.  
 
The KCC2a isoform could, however, be involved in the development of hyperexcitability 
and seizures in some brain regions. For example, in temporal lobe epilepsy, the most 
common type of acquired epilepsy in adults, downregulation of KCC2 mRNA and 
subsequent depolarizing GABAergic events has been observed in the hippocampal 
subiculum in human epileptic tissue (Palma et al, 2006, Huberfeld et al, 2007). When temporal 
lobe epilepsy was induced in rats by pilocarpine, a downregulation of KCC2 mRNA in many 
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parts of the hippocampal formation, including subicular neurons, was observed (Bragin et al, 
2009, Barmashenko et al, 2011). Since the KCC2a isoform was exceptionally detected in the 
subiculum in immunohistochemistry stainings (study II), both KCC2a and KCC2b 
downregulation could potentially play a role in the initiation and maintenance of epileptic 
discharges in temporal lobe epilepsy. 
 
In pyramidal neurons of the rat hippocampus, an activity-dependent increase in the surface 
expression of both KCC2 isoforms has been demonstrated during the first postnatal week 
(Khirug et al, 2010): A single kainite induced in vivo seizure episode during postnatal days 5–
7 resulted in a fast increase in the Cl− extrusion capacity of CA1 neurons, with a consequent 
hyperpolarizing shift of the reversal potential of GABAA-mediated currents. Biochemical 
data demonstrated an approximately twofold increase in the plasmalemmal pool of both 
KCC2a and KCC2b isoforms in the CA1 region. Thus, regulation of the surface expression 
of KCC2 isoforms may represent an intrinsic antiepileptogenic mechanism in neonates. 
 
Following peripheral nerve injury, a reduction in KCC2 expression and activity has been 
observed downstream from the injured neurons, in lamina I of the superficial dorsal horn 
(Coull et al, 2003). Spinal cord neurons in lamina I receive inputs from pain-conducting C-
fibers and project the pain signal to the brain, thus these neurons constitute one of the main 
spinal nociceptive output pathways. Cl− accumulation and change in GABAA-mediated 
responses may cause normally inhibitory anionic synaptic currents to be excitatory. 
Antibodies that recognize both KCC2 isoforms were used in this study, and thus 
downregulation of both KCC2a and KCC2b expression/activity could be involved in the 
attenuated inhibitory action of GABA and glycine in central sensitization of the spinal cord.  
 
In rats, spinal cord injury induced a downregulation of KCC2 in the spinal cord below the 
lesion, in the plasma membrane of motoneurons resulting in increased excitability of 
motoneurons and contributed to spasticity (Boulenguez et al, 2010). Also in this study, 
antibodies recognizing both KCC2 isoforms were used. 
 
In study III, a similar ion transport activity of KCC2 isoforms was demonstrated in neuronal 
cells. The KCC2a isoform was able to mediate K-Cl cotransporter activity in overexpression 
experiments in KCC2-null neurons and in immature wild-type neurons. In line with this, 
KCC2a also appears to be functional in ion-transport in vivo, as KCC2b-deficient mice survive 
up to three weeks postnatally (Woo et al, 2002). The KCC2a N-terminal domain includes an 
SPAK-binding domain, and in study III we demonstrated that overexpressed SPAK in 
HEK293 cells bound to the N-terminus of KCC2a, but not that of KCC2b. Different 
regulation of the transport activity of the isoforms by SPAK was also observed in HEK293 
cells in study III. Thus, the isoform-specific N-terminal parts could have important regulatory 
properties.  
 
Phosphorylation is known to play a crucial role in the regulation of the intrinsic transport 
function of KCC2. For example, S940 in the C-terminal domain of KCC2 is a site for protein 
kinase C (PKC), and phosphorylation at S940 has been shown to increase the transport rate 
of KCC2 and stability at the plasma membrane (Lee et al, 2007, Lee et al, 2011). In contrast, 
52 
 
KCC2 activity at the plasma membrane can be inhibited by WNK-SPAK kinases at 
T906/T1007 (Kahle et al, 2016). Studies have also shown that KCC2 is more highly 
phosphorylated at T906/T1007 by WNK-SPAK in immature neurons compared to mature 
neurons (Friedel et al, 2015). Thus, regulation by WNK/SPAK kinases and 
dephosphorylation at T906/T1006 seems to be important in postnatal activation of KCC2 
function.  
 
Since the WNK-SPAK pathway is important for the GABA shift in development (Friedel et 
al, 2015), a major open question is whether the difference in T906/T1007 phosphorylation 
in development is KCC2 isoform-specific and how the phosphorylation (and thus activity) 
of the KCC2 isoforms by WNK-SPAK pathway differs in neurons during postnatal 
development. Thus, the phosphorylation profile of KCC2 isoforms should be further investigated in primary 
neurons during development.  
 
The regulation of KCC2 activity via the WNK-SPAK pathway also appears to be important 
in neuropathic pain: Mutation in a WNK1 isoform that is expressed in the nervous system, 
and particularly in the dorsal horn of the spinal cord, results in hereditary sensory and 
autonomic neuropathy type IIA (HSANII) in humans. A knockout mouse specifically lacking 
this WNK1 isoform had less phosphorylation of KCC2 at T906 and T1007 in the spinal cord 
and an increase in KCC2 activity, and the mice were less susceptible to hypersensitivity after 
peripheral nerve injury (Kahle et al, 2016). KCC2 T906 and T1007 phosphorylation was 
decreased and EGABA was restored to more negative values in lamina II neurons from mice 
with nerve injury by slice incubation with STOCK1S-50699 (an inhibitor of the WNK-SPAK 
pathway), resulting in reduced cold allodynia and mechanical hyperalgesia (Kahle et al, 2016). 
 
Since chronic neuropathic pain is often resistant to treatment, a novel potential analgesic 
strategy in neuropathic pain would be to restore GABA-mediated inhibition by enhancing 
KCC2 activity in dorsal horn neurons (Gagnon et al, 2013). Pharmacologically antagonizing 
the WNK/SPAK pathway would promote combined NKCC1 inhibition and KCC2 
stimulation, also yielding a potent strategy to enhance cellular Cl− extrusion and the GABA 
inhibition in neuropathic pain after nerve injury (Kahle et al, 2013). Since both KCC2 isoform 
are expressed in the spinal cord, KCC2a could also contribute to pain hypersensitivity after 
nerve injury, particularly since regulation by WNK-SPAK pathway seems to be critically 
involved. An interesting question is also the difference between the phosphoregulation of KCC2a vs. KCC2b 
by the WNK-SPAK pathway after trauma. 
 
Novel specific and potent pharmacological compounds that modulate KCC2 activity have 
been identified in high-throughput screens. To further study the differences between the two isoforms, 
the isoform-specificity of these compounds could be tested in HEK293 cells overexpressing KCC2 isoforms. 
For example, the KCC2 selective antagonist VU0463271 has been discovered that efficiently 
inhibited KCC2b overexpressed in HEK293 cells in Rb uptake assay (Delpire et al, 2009, 
Delpire et al, 2012). However, VU0463271 was found to have poor pharmacokinetic 
properties, because of rapid metabolism (Delpire et al, 2012). In vivo infusion of the inhibitor 
into hippocampus of adult WT mice resulted in hyperexcitability and epileptiform discharges 
in the hippocampal slices (Sivakumaran et al, 2015). Experiments with VU0463271 also 
53 
 
demonstrated that reduced KCC2 transport increased the duration of seizure-like events in 
acute mouse brain slices in the 0-Mg2+ model (Kelley et al, 2016). 
  
KCC2 activators would potentially be of use therapeutically, in the treatment of epilepsy, 
neuropathic pain and other disorders. So far, a KCC2-selective enhancer, CLP257, has been 
discovered that significantly increased the rate of Cl− accumulation and alleviated 
hypersensitivity in a rat model of neuropathic pain (Gagnon et al, 2013). The CLP257 
compound appears to modulate plasmalemmal KCC2 protein turnover, most likely by 
inhibiting internalization of KCC2. Although the mechanism has not been fully resolved, it would also 
be useful to determine possible isoform-specific effects of this this compound. 
  
By confocal immunofluorescence microscopy, a partially different distribution of KCC2a and 
KCC2b at the subcellular level was observed in the dendritic compartments of mature 
neurons in mouse brain sections (Study II). KCC2a was seen in discrete puncta particularly 
in distal dendrites which did not always co-localize with KCC2b. Distinct isoform-specific 
compartmentalization might suggest unique functions of the isoforms in neurons. It is 
possible that the unique N-terminal regions of the isoforms dictate their subcellular 
localization by interacting with different trafficking elements. KCC2 isoforms might 
accumulate in different subdomains at the plasma membrane, for example in lipid rafts. 
Alternatively, KCC2a specific puncta may represent accumulation in intracellular 
compartments in distal dendrites. A future task would be to address the different subcellular localization 
of KCC2 isoforms within distal dendrites using electron microscopy. 
  
Differential surface expression of KCC2 isoforms was also observed in immunostainings. 
KCC2b signal was present at the plasma membrane throughout the somatodendritic 
compartments, while KCC2a was not detected at the neuronal plasma membrane in most 
brain regions in mouse sections (Study II and III). In a few brain regions (most clearly seen 
in the subiculum in study III) KCC2a immunoreactivity was detected at the cell surface. In 
primary rat cortical or mouse hippocampal neuronal cultures, KCC2b but not KCC2a 
immunoreactivity was observed nearby the plasma membrane surface of soma and proximal 
dendrites (Study III). However, biotinylation experiments indicated that both isoforms were 
expressed to a similar extent at the neuronal plasma membrane, suggesting that the KCC2a 
N-terminus at the cell surface may be masked. Masking could suggest that KCC2a is also at 
the membrane in vivo even if we do not detect this in most brain regions (indeed 
immunohistochemistry data from KCC2b knockout mice in study III support the masking 
in vivo).  
 
Protein interactions, oligomerization, phosphorylation or other modifications could mask the 
KCC2a N-terminal epitope at the neuronal surface. Since a differential interaction of the 
KCC2 isoforms with SPAK was demonstrated in HEK293 cells, SPAK could be one possible 
candidate responsible for masking of the KCC2a N-terminal epitope. On the other hand, the 
N-terminal epitope could also be masked by not yet identified protein interactions. It would 
be useful in mass spectrometry experiments to determine the KCC2a N-terminal binding partners in neuronal 
cultures, as well as to directly confirm the binding of SPAK. Identifying KCC2a –specific interacting 
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partners should aid in determining the mechanism of masking, and also help to clarify the 
specific role of the KCC2a isoform in neurons. 
 
KCC2 has been shown to engage in a variety of protein-protein interactions. Recently, a 
global KCC2 interactome study was performed by affinity purification of KCC2 from mouse 
whole brain membrane fractions (Mahadevan et al, 2017). High-resolution mass spectrometry 
analysis revealed 150 previously unknown native-KCC2 interactors in mouse brain. Some of 
the interacting partners were enriched exclusively from mature brain and others only from 
developing brain (P5). While isoform specific-interactions were not determined in this study, 
it was observed that different detergents extracted KCC2 isoforms differentially together 
with largely different subsets of proteins, indicating that detergent stabilities of KCC2 
isoforms and their associated protein complexes are different.  
 
Many of the new interacting partners that were identified in the global KCC2 interactome 
study were exclusively enriched at excitatory synapses and particularly many were involved 
in receptor trafficking (Mahadevan et al, 2017). The most abundant KCC2 interactor in this 
study, PACSIN1, is a neuronal endocytic adapter protein that regulates the surface expression 
of distinct glutamate and glycine receptors.  
 
Various ion-transport-independent roles of KCC2 in spinogenesis has been demonstrated 
through structural interactions with components of the actin cytoskeleton. KCC2-deficient 
neurons demonstrated an aberrant maturation of dendritic spines and a decrease in the 
number of functional synapses (Li et al, 2007, Gauvain et al, 2011). Dendritic spines of KCC2-
deficient neurons exhibited increased stability of actin filaments and reduced spine motility 
(Llano et al, 2015). In mature hippocampal cultures, immunostaining with KCC2 pan-
antibodies demonstrated that KCC2 is expressed at higher levels in mushroom spines (with 
active synapses) and at lower levels in filopodia (Llano et al, 2015). 
 
The structural interactions important for morphology and function of spines seem to involve 
the common C-terminal domain of KCC2 (Chevy et al, 2015, Li et al, 2007, Llano et al, 2015), 
and the interactions could thus engage both isoforms. However, KCC2b is widely expressed 
in cortical regions and its upregulation in development temporally parallels spinogenesis and 
excitatory synaptic maturation. KCC2a is for the most part not expressed in cortical regions, 
and is thus supposedly not important in spines. However, KCC2 isoforms could also be 
involved in actin regulation in other cellular compartments in addition to spines, although 
this aspect has not yet been studied. A specific structural role of KCC2a is also possible, 
perhaps via sites of interaction in the unique N-terminal part.  
 
In conclusion, the isoform-specific functional role of KCC2a remains to be studied. Different 
underlying regulatory mechanisms and post-translational modifications are presumably 
important in defining the unique functions of isoforms in neurons. Further work is required 
to understand in detail how the WNK-SPAK pathway controls phosphorylation and activity 
of the KCC2 isoforms in hetero- as well as homodimers. In addition, a specific role of the 
KCC2a isoform outside the CNS is also possible, and remains to be studied in future 
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experiments. Ongoing and planned studies in KCC2a knock out mice are seeking to answer 
the question of the KCC2a role in vivo.  
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